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ABSTRACT

Environmental estrogens pose potential health risks to humans and wildlife by
disrupting physiological and developmental processes; therefore, our laboratory has been
designing in vivo bioassays on induction of the egg-yolk precursor protein vitellogenin. I
have provided information on vitellogenin induction by estrogens in tiger salamanders
(Ambystoma tigrinum), spotted salamanders (Ambystoma maculatum), hellbenders
(Cryptobranchus alleganiensis), Morelet’s crocodiles (Crocodylus moreletii), and
developed vitellogenin immunoassays in these species. Salamanders were estrogeninjected; blood was collected at intervals. Estrogen exposed male salamanders of all
species, produced substantial quantities of a 200-kDa protein, the approximate size of
vertebrate vitellogenins. Sequencing of estrogen-induced proteins showed substantial
homology to known vertebrate vitellogenins. Tiger salamander vitellogenin N-terminus
antibodies were produced, and crossreacted with serum from estrogen-treated but not
control tiger salamanders. Vitellogenin assays for these species could study annual
reproductive cycles, test waters for the presence of estrogenic agents or assess exposure
of wild populations to environmental estrogens.
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Introduction

In the early 1970’s, on a small, secluded street in Pittsburgh, PA there was a group of
residents whose properties were near an automobile junkyard. These same residents, their
children, and even grandchildren, seemed to be predisposed to a variety of illnesses, ranging
from serious thyroid conditions to miscarriages to even various forms of cancers. It was not until
years later that this junkyard was discovered to be a dumpsite for toxic waste and chemicals, in
particular polychlorinated biphenyls (PCBs). The chemicals were suspected to be giving the
residents the predisposition to these illnesses, and are now classified with many other chemicals
as endocrine disruptors.
According to the endocrine disruptor hypothesis, there are “certain chemicals (primarily
man-made) that act as, or interfere with, human hormones (specifically estrogens) in the body,
and thus cause a range of defects and diseases related to the endocrine system” (Lukachko,
1999). Some endocrine disruptors are extremely harmful to humans due to their persistence in
the environment, high lipophilicity, long half-life, high bioaccumulation, and low rate of
biodegradation. Once they enter into our environment, it is a very long, hard road to removal. In
order to better understand how endocrine disruptors may interfere with our endocrine system, it
is important to understand how hormones normally function.
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Steroid Hormones

Hormones are substances secreted by an endocrine gland or cell into the blood, where
they may exert regulatory activity, typically in cells other than those in which they were
produced, which result in a response depending on the presence of a specific receptor (O’Malley
and Strott, 1991; Carlstedt-Duke et al., 1995). Steroid hormones are a class of molecules that
regulate gene functions associated with specific developmental and physiological processes.
Steroid hormones are divided into six major classes; estrogens, progestins, androgens,
glucocorticoids, mineralocorticoids, and vitamin D derivatives. These hormonal classes show a
high degree of similarity in structure but have widely different functions (O'Malley and Strott,
1991; Baulieu, 1984). Estrogens are involved in regulating female reproduction, androgens are
involved in regulating male reproduction, progestins aid in pregnancy, glucocorticoids regulate
aspects of metabolism and stress responses, mineralocorticoids assist in salt metabolism, and
vitamin D and its derivatives are important in bone metabolism (O'Malley and Strott, 1991;
Bolander, 1994).
Steroid hormones are secreted by a variety of glands into the bloodstream, where they
circulate bound mostly to plasma transport proteins. These hormones, being lipophilic, can
diffuse across the plasma membrane and into cells. In the target cells, steroid hormones combine
with their specific receptors, and the hormone/receptor complex then alters cell function
(O'Malley and Strott, 1991; Korach, 1994; McMaster et al., 2001). Receptors for some steroids
are present in most cells; for example, those for mineralocorticoids and glucocorticoids.
However, receptors for other steroids are present in more limited cell types; for example,
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receptors for estrogens are present mostly in female reproductive tissues, and receptors for
androgens are present mostly in male reproductive tissues.
Regardless of the type of steroid hormone, all operate through a similar mechanism. In
order for steroid hormones to regulate specific functions, they must bind to and activate
receptors, which are gene-regulatory molecules. The receptors bind steroid hormones very
tightly and are extremely specific; they are also present in low concentrations in cells. Upon
binding of the hormones to their specific receptors, the receptors undergo a conformational
change, which alters the receptor from an inactive to an active state. Before binding, the
receptors are associated with chaperone proteins, more specifically known as heat shock
proteins. Binding results in the dissociation of the chaperone protein and allows the hormone
receptor complex to interact with the genome by binding to the DNA at specific sites within
hormone-dependent genes (Carlstedt-Duke et al., 1995). Binding of the hormone/receptor
complex to the regulatory elements of genes either activates or suppresses their transcription.
In early studies it was thought that unliganded steroid receptors resided in the cytosol,
and after hormone binding, the hormone/receptor complex moved into the nucleus. It was later
found that even in the absence of the hormone, some receptors reside in the nucleus (CarlstedtDuke et al., 1995; Smith and O’Malley, 1999). The steroid hormone receptor is comprised of
three distinct functional domains. The first is the amino-terminal domain, which regulates
transcriptional activity. The second is the DNA-binding domain, which is responsible for
dimerization, DNA-binding, and some transcriptional functions. The third is the carboxyterminal domain, which contains the hormone-binding site and interacts with the chaperone
proteins (Carlstedt-Duke et al., 1995). The receptor’s hormone-binding domain recognizes the
three-dimensional configuration of a particular hormone with high affinity, and has low affinity
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for other hormones. In the absence of hormones, the receptor protein binds to a heat shock
protein (usually hsp90). The role of the heat shock protein is to maintain the correct folding of
the receptor and to mask the DNA-binding site of the receptor protein, blocking genome
interactions in the absence of the appropriate steroid hormone (Carlstedt-Duke et al., 1995). Not
only do the heat shock proteins assist in folding, they also protect the receptors from degradation
via cellular proteases (O'Malley and Strott, 1991). After the hormone binds to the receptor, the
hormone/receptor complex binds to the DNA as dimers. Because dimers bind more tightly and
stably than a monomer, they have a greater effect on gene expression (O'Malley and Strott, 1991;
Toft et al., 1967).
Once the receptor has become activated, it alters cell function by binding to the DNA at
specific sites called hormone-response elements (HREs), which are specific sequences of DNA
located near hormone-dependent genes (Carlstedt-Duke et al., 1995; Nawaz et al., 1992). The
hormone response elements are characterized by short inverted repeats separated by a fixed
number of nucleotides, which varies depending on the steroid receptor types (Carlstedt-Duke et
al., 1995; O'Malley and Strott, 1991; Nawaz et al., 1992; Ryseck et al., 1989). Binding of the
hormone-receptor complex to HREs causes a disruption of the chromatin structure, supplying a
naked region of the DNA. By modulating the chromatin structure, access is allowed to
transcription factors (Carlstedt-Duke et al., 1995; O'Malley and Tsai, 1992; Ryseck et al., 1989).
The receptor attracts transcription factors and RNA polymerase to transactivation domains on the
receptor, initiating transcription. The production of mRNA via gene transcription requires the
binding of transcription factors and RNA polymerase to the gene promoter to form a complex
(Carlstedt-Duke et al., 1995; O'Malley and Tsai, 1992).
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Endocrine Disruptors

Endocrine disruption is a topic that has received increased attention due to the actions and
dedication of environmental activists beginning with Rachel Carson (and her book Silent
Spring), and more recently followed by Theo Colburn (and her book Our Stolen Future).
Considerable quantities of potentially endocrine disrupting chemicals are mass-produced and
introduced into the environment each year. Endocrine disruptors have been defined as
“exogenous agents that interfere with the production, release, transport, metabolism, binding
action or elimination of natural hormones in the body responsible for the maintenance of
homeostasis and the regulation of developmental processes” (Ginsburg, 1996). Alternatively, the
Environmental Protection Agency (EPA) defines endocrine disrupting chemicals to be agents
leading to toxic outcomes such as various types of cancer and a whole host of adverse
reproductive effects (Kavlock, 1997). They range in chemical structure from pesticides,
chlorinated compounds, plasticizers, to even the breakdown components of household detergents
(Lukachko, 1999).
Endocrine disruptors exert their deleterious effects by interfering with the normal
functioning of the endocrine system. The endocrine system is a complex communication system
regulating normal growth, development, reproduction, behavior and physiological functions of
humans and animals. There are a variety of sectors that work together to make up this system,
including the adrenal cortex, ovaries, testes, pituitary, thyroid, and the parathyroid (Lukachko,
1999). These glands secrete hormones, which act as information carriers, to activate specific
receptors in tissues and organs throughout the body. The most horrific effects of environmental
contaminants are mediated by their ability to mimic these natural hormones in the body. The
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most prominent and pervasive of these endocrine disruptors are those known to mimic the steroid
hormone estrogen. While some synthetic compounds were manufactured to be estrogenic, most
were not designed to have endocrine functions, and are inadvertently estrogenic (termed
xenobiotic estrogens).
Exposure of humans to endocrine disruptors has been suggested to cause a number of
health problems, including: increased risks of cancers (breast, prostrate, and testicular), reduced
sperm counts, birth defects to the reproductive organs, problems in pregnancy, and effects on the
thyroid gland (Lukachko, 1999; Danzo, 1998). Endocrine disruptors are insidious because they
affect the endocrine system by mimicking natural hormones, and often the effects are not noticed
until after a large time lapse. For many chemicals, the exposure may occur in one generation
(e.g., a pregnant mother), and may not cause any harm at all to this generation; however, the
compound may elicit its deleterious effects on the second generation (e.g., the progeny of the
mother). Even though the effects from these chemicals on one generation may be very minimal,
if they are experienced at critical stages in development, they can lead to permanent, devastating
effects on a second-generation developing fetus.
Not only are the effects of endocrine disrupting chemicals potentially so grave on
humans, they are also known to be devastating to wildlife populations. The current decline of
amphibian populations may reflect a worldwide trend of environmental degradation. Endocrine
disruption in wildlife populations is far from consistent; it ranges from crossed beaks in birds, to
alligators with small penises, to the disappearance of entire populations. Chemicals contaminate
the habitats of fish and wildlife; these chemicals can permeate through the skin of amphibians,
accumulate in the animal’s endocrine systems, and cause serious defects. These endocrine
disrupting chemicals, due to their persistence in the environment, bioaccumulate in the fatty
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tissues of organisms, and increase in concentration as they move up throughout the food web,
harming species far from the original source of contamination. The most prominent effects upon
wildlife populations are: thyroid system disorders, inability to breed, abnormal mating and
parenting, interrupted sexual development, and reduced immune response (Colborn et al., 1993;
Hayes et al., 2002; Clark et al., 1998; Raloff, 1994; Carey and Bryant, 1995). The most
prominent studied populations are: sea gulls, harbor seals, bald eagles, oysters, snails, fish,
whales, trout, panthers, alligators, turtles, other types of reptiles and birds (Shimasaki et al.,
2003; Kavlock, 1997; Toppari et al., 1996). Recently considered potential sources of endocrine
modulators which affect wildlife are: runoff from sewage treatment plants, pulp/paper mills, and
other manufacturing factories (Luchako, 1999). An example is the increased amount of women
using birth control. This places an increased amount of estrogen and their breakdown products
through sewage treatment plants and into the waterways, leaving wildlife at a disadvantage
because these waters serve as nurseries for offspring and breeding ponds for mature animals.
These environments may be triggering endocrine related effects in fish and aquatic amphibian
populations.
A number of potential endocrine disruptors have been identified. Some important ones
are 1) DES, 2) DDT, 3) PCBs, and 4) a number of contemporary contaminants.
Diethylstilbestrol, or DES, is a pharmacological agent manufactured to have estrogenic activity.
Although DES is structurally dissimilar to natural estrogens, it exhibits similar biological
functions and hence, is an example of the worst-case scenario for endocrine disruption
(McLachlan, 2001; Denslow et al., 2001). This drug was prescribed for the prevention of
miscarriages in the 1950s through 1970s. The daughters of women who took this drug
experienced increased numbers of defects (in the vagina, uterus, and Fallopian tubes),
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reproductive cancers (known as clear-cell adenocarcinoma), sexual deformities and sterility.
Consequently, DES has been described as the first transplacental carcinogen, a chemical that
causes cancer in the daughter when administered to the mother (McLachlan and Arnold, 1996).
Not only was this compound harmful to female offspring of treated mothers, but it also has
resulted in increased frequency of undescended testicles, sperm abnormalities, prostrate disease,
and testicular cancers in male offspring (McLachlan and Arnold, 1996; Palmer et al., 2001).
DDT and PCBs are endocrine disrupting chemicals no longer in wide use; nevertheless,
they still have great importance due to their perseverance in the environment. The first
recognized class of endocrine disruptors was the pesticide dichlorodiphenyltrichloroethane,
better known as DDT. This compound was manufactured primarily as a malaria control agent,
whose effectiveness allows it to still be used in some third world countries (Mbongwe et al.,
2003). Being an artificial estrogen, DDT is most notably the best studied example of an
exogenous hormone mimic (Mbongwe et al., 2003; Bustos, 1988). DDT was considered an ideal
chemical because it was extremely persistent in the environment, had a high toxicity to
invertebrates, and was thought to have a low toxicity to vertebrates. However, DDTs
bioaccumulating effects resulted in elevated levels at the top of the food chain. Prior to being
banned in the United States in 1972, DDT was found to induce poor survivorship, antibody
response suppression, reduced reproductive success, reduced sperm counts, and eggshell
thinning in a variety of birds, including seagulls, and particularly bald eagles (Gilbertson et al.,
2003; Lukachko, 1999; Bitman and Cecil, 1970; Bustos et al., 1988; Raloff, 1994, McLachlan
and Arnold, 1996). Since the 1980’s, DDT has been identified as a wildlife feminizing chemical
(McLachlan and Arnold, 1996) and also has shown to increase uterine weight in rats, prolong
estrous cycles, and decrease ova implantation in mice (Bitman and Cecil, 1970). DDT inhibits
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the enzyme Ca-ATPase, a calcium transporter from the blood to the oviduct, which induces
eggshell thinning (Fairbrother et al., 1999). Although the mechanism of DDT action is
controversial, the most widely accepted theory is that DDT binds to the cellular estrogen
receptor, initiating the same sequence of events as the natural estrogen hormone does
(Fairbrother et al., 1999). This stimulates the increase in uterine DNA synthesis, protein
synthesis, and secretion (Stancel et al., 1995). The breakdown products of DDT may act as
estrogens, or even compounds that block androgens. DDT has also been reported to disrupt the
sodium/potassium exchange between neurons (Fairbrother et al., 1999).
Another class of endocrine disruptors used widely in the past are the chemicals called
polychlorinated biphenyls, better known as PCBs. The best-known human example is in
Anniston, Alabama, where PCBs can still be found in the air, water, soil, wildlife, and even in
the residents themselves (Kroft, 2002). PCB exposure resulted in deformed fish, liver damage in
exposed rats, and possibly causing cancer, heart disease, and diabetes in the town population.
PCBs have also been shown to have effects on exposed bird populations by feminizing the male
sex organs of exposed seagulls and causing a life-threatening bill deformity in the cormorant
(Raloff, 1994; Fairbrother et al., 1999; McLachlan and Arnold, 1996). PCBs are similar to DDT
in that they can have reproductive defects, induce uterotropic effects, stimulate prolonged estrous
cycles, and impair fertility (Selcer et al., 2001; de Solla et al., 2002; Blais et al., 2003). Some of
these compounds have been shown to become even more estrogenic as they are metabolized by
the body (McLachlan and Arnold, 1996; Bergeron et al., 1994). Various PCBs are adept at
binding to the aryl hydrocarbon receptor, estrogen receptors, thyroid hormone receptors, and
several receptors in the liver. When binding to estrogen receptors, PCBs may either interfere
with or initiate the same sequence of events as the natural estrogen hormone does (Fairbrother et

9

al., 1999; Korach, 1994). Some PCBs are proficient at antagonizing the natural estrogen actions,
and also can cause the conversion of androgen to estrogen in some cells, impairing masculinity
(Colborn, 1995; Bitman and Cecil, 1970; Bergeron et al., 1994).
While DES, DDT, and PCBs are of considerable historical importance, these substances
are no longer in use in the U.S., and are now limited in their distribution. However, other
chemicals have recently been recognized as frontrunners in endocrine disruption importance.
Alkylphenols and their relatives, alkylphenol polyethoxylates (APEOs), are environmental
contaminates that have proven estrogenic activity. These compounds are used in pesticides,
detergents, paints, and even cosmetics (Danzo, 1998; Soto et al., 1991). Two of these
compounds, nonylphenol and octylphenol, products of APEO degradation by microorganisms
(Soto et al., 1991), are very stable in the environment and estrogenic in different model systems:
for example, newts and frogs (Pfister et al., 2003; Mosconi et al., 2002). They have also been
found to cause male reproductive deficits (Danzo, 1998). Two plasticizers, bisphenol-A and
phthalate esters, are some of the most prevalent man-made chemical pollutants in the aquatic
environment. These have both been shown to be estrogenic in vertebrates and invertebrates alike
(Hutchinson, 2002; Danzo, 1998; Turner and Sharpe, 1997; Soto et al., 1995). A recent leader in
the field; atrazine is the most commonly used herbicide in the United States, and probably in the
world. Atrazine affects sexual differentiation, by inducing aromatase, which converts androgens
into estrogens (Hayes et al., 2002; Dankwardt, 1998). In agricultural runoff alone, atrazine can
be present at several parts per million, and can reach up to 40 parts per billion in precipitation
(Hayes et al., 2002). Amphibians breeding in watersources such as streams, rivers, and lakes,
can be exposed to very high concentrations of atrazine.
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The relationship between wildlife and human abnormalities, diseases, and dysfunctions of
the endocrine system and exposure to environmental contaminants is not fully understood and
the subject of intense debate. Thus, there is a pressing need for assays capable of detecting
endocrine disruptors and assessing their effects. There are three areas of utility for endocrine
disruptor assays. 1) Testing compounds for endocrine disrupting effects; 2) Testing animal
populations for exposure to such agents, and 3) Testing waters that are suspected to contain
environmental contaminants.
To address these needs, Congress passed the Safe Drinking Water Act and the Food
Quality Protection Act, which mandated that the EPA develop testing to characterize and detect
the endocrine activity of pesticides, commercial chemicals, and environmental contaminants.
These acts stated that EPA must develop an endocrine disruptor screening program, and then
screen for endocrine disruptors in drinking water sources. The committee called EDSTAC
(Endocrine Disruption Screening and Testing Advisory Committee) designed and implemented
the program which focuses on providing methods and procedures to detect and characterize the
endocrine activity of pesticides, commercial, and environmental contaminants (EDSTAC, 1998).
This program was enabled to provide the most scientific data available for 87,000 plus chemicals
in commerce (EDSTAC, 1998). Those endocrine disruptors will be identified and regulatory
action will be enforced. Currently, the EPA is in the process of initial screening (via Tier I
screening) and testing (via Tier II testing) of chemical substances that may have an effect similar
to that produced by naturally occurring hormones in the body.
Many times what is troubling when evaluating endocrine disruptors is that the chemical
structure of the synthetic compound may not resemble that of the natural hormones they mimic,
therefore making it hard to predict which compounds will be endocrine disruptors. Even though
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many synthetic chemicals were not manufactured with the intent of inducing hormonal activity,
in some way they obtain the ability to alter the endocrine system (McLachlan and Arnold, 1996;
Bitman and Cecil, 1970). Since the compounds may be structurally different than hormones, a
chemical assay often cannot be used. Thus, biological assays must be used in order to assess the
endocrine disrupting potential of compounds.
Endocrine disruption assays can be in vitro or in vivo. Each of these approaches has
advantages and disadvantages. Some advantages of in vitro methods are cost, rapid detection,
small amounts of material required, technique automation, complex mixtures can be tested, and
there is a high specificity of response (Gray et al., 1997). The disadvantage of in vitro assays are
they can provide both false positive and false negative results by not taking into account the
physiology of the organism. The false positive results occur when a chemical is rapidly
metabolized, is not absorbed or distributed to the target tissue, or is toxic in a different form in
vivo (Gray, 1998; Gray et al., 1997). False negatives occur in vitro due to the inability to
metabolically activate certain toxicants. The in vitro estrogenicity assays currently being used
include the estrogen/androgen receptor reporter gene assays (Gray, 1998; Gray et al., 1997;
EDSTAC, 1998), vitellogenin induction in trout hepatocytes (Pelissero et al., 1993), and growth
of estrogen-dependent breast cancer cells (Soto et al., 1992; Arnold et al., 1996). In vivo
advantages include accountability for absorption, distribution, metabolism, and excretion of the
estrogenic chemical, the endpoints can be used in risk assessment, applicable over a wide-range
of species, evaluation of the endocrine system as a unit, and it provides perspective to other
toxicity endpoints (Gray, 1998; Gray et al., 1997). The disadvantages of the in vivo assays are
they are very costly and it takes a long time to complete the assay. The in vivo estrogenicity
assays that the EPA is currently proposing for screening are the rodent uterotrophic assay, the
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rodent pubertal male/female assay, the fish reproduction assay, and the rodent reproduction assay
(Turner and Sharpe, 1997; Soto et al., 1992; Soto et al., 1995). Another test created to assess
estrogenicity is based on induction of vitellogenin in nonmammalian vertebrates (Palmer et al.,
1998; Heppell et al., 1995; Sumpter and Jobling, 1995).
Testing animal populations and watersheds for the exposure and presence of endocrine
disrupting chemicals is difficult because there is a need for background information for each
species used, and a need for assays for each animal to test for estrogenicity. There are several
basic field studies that can be used for testing. The first design is to place a prescreened animal
into a test site, remove the animal after a specific time interval, and then check for endocrine
disruption (Sumpter and Jobling, 1995; Purdom et al., 1994; Folmar et al., 2001; Folmar et al.,
1996). The second design is a lab test involving removal of water from a suspected area,
bringing it to the lab and testing it on an animal model (Sumpter and Jobling, 1995; Purdom et
al., 1994; Folmar et al., 2001; Folmar et al., 1996).
The aforementioned vitellogenin assays have many advantages, such as cost, the use of
aquatic organisms, and the ability to test waters for the occurrence of estrogenic contaminants
(Bringolf and Summerfelt, 2003; Purdom et al., 1994; Folmar et al., 2001; Folmar et al., 1996;
Selcer and Palmer, 1995). There is a lack of whole animal in vivo assays, and there is a lack of
amphibian information, specifically salamander information. The lack of whole animal assays is
particular troubling, especially since the majority of the assays performed thus far have only
focused on fish populations. There is a need for biological assays that are capable of detecting
physiologically relevant concentrations of xenobiotic estrogens in the remainder of the aquatic
community. Even though there have been few studies on aquatic reptiles and amphibians, their
numbers continue to decline. Salamanders, one type of amphibians, are rapidly declining, and
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even though endocrine disruption is suspected, there have yet to be any studies to support this
hypothesis. In this project, I have studied the regulation of vitellogenin and other serum proteins
by estrogens in the tiger salamander, Ambystoma tigrinum.

Vitellogenin as a Biomarker

Vitellogenin is a large serum phospholipoglycoprotein that is a precursor molecule to the
egg-yolk proteins of oviparous vertebrates (Ho, et al., 1982; Ho, 1987; Ho, et al., 1981). In a
developing embryo, egg-yolk proteins are the source of metabolic energy. In mature female nonmammalian vertebrates, the liver, in response to circulating estrogens, synthesizes and secretes
vitellogenin into the bloodstream (Ho, et al., 1982; Ho, 1987; Ho, et al., 1981). The vitellogenin
is taken up from the bloodstream by the developing oocytes, and then cleaved into lipovitellins
and phosvitins, the egg-yolk proteins (Selcer and Palmer, 2001). Vitellogenin is not normally
present in the plasma of males and immature females; however, it is inducible by estrogen
treatment. Estrogen promotes vitellogenesis in members of all non-mammalian classes (Ho et
al., 1982; Ho, 1987; Smith and O’Malley, 1999). Although other factors play a role in
modulating a vitellogenic response (Ho et al., 1982; Ho, 1987; Wangh, 1982; Wangh and
Schneider, 1982), estrogen is the primary inducer of vitellogenin (Tata and Smith, 1979).
Induction of vitellogenin may be a way to show evidence of exposure to endogenous or
exogenous estrogens (Heppell et al., 1995; Denslow et al., 1995). Vitellogenin is normally
female specific, but is inducible in male animals by estrogen and estrogenic compounds (Palmer
et al., 1998; Selcer et al., 2001). This presence of vitellogenin in the male animal can be used as
an indicator of exposure to xenobiotic estrogens. Since the structures of environmental estrogens
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are dissimilar, this provides an assay that is capable of measuring estrogenic exposure for a
number of various compounds to attempt in identifying environmental pollutants. Thus,
vitellogenin can serve as a biomarker for environmental estrogens.

Estrogen Regulation of Other Serum Proteins

Along with induction of vitellogenin, estrogen action may cause other proteins to change,
which can also serve as biomarkers. Selcer and Palmer, 1995 and Shapiro, et al., 1989
demonstrated in frogs and turtles that estrogen treatment results in the down regulation of major
serum proteins. In the turtle, albumin, with a molecular weight of 66kDa, and a second
unclassified protein, with a molecular weight of 170kDa, were both down regulated (Selcer and
Palmer, 1995). Estrogen treatment decreased both proteins by about 50% as compared to the
controls. This finding is significant because it helps to establish the prevalence and importance
of the estrogen down regulation mechanism (Selcer and Palmer, 1995).
Estrogen is important in female vertebrates for the maturation and preparation of the
reproductive tract, development of secondary sexual characteristics, and stimulation of
vitellogenesis (Selcer and Leavitt, 1991). The predominant mechanism of estrogen action is
through the control of cellular protein synthesis, and it is known to up regulate and down
regulate a number of serum proteins. Two common examples of enhanced protein synthesis via
estrogen are ovalbumin production by the avian oviduct (O’Malley et al., 1969) and vitellogenin
production by the amphibian liver (Hayward et al., 1982). In contrast, estrogen represses the
estrogen receptor in the MCF-7 human breast cancer cell line (Read et al., 1989) and results in
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the disappearance of a number of serum proteins, the most widely studied of which is albumin
(Follett and Redshaw, 1974; Pastori et al., 1991; Jackson and Shapiro, 1986).
Estrogen down regulation of specific proteins may represent an important and
understated aspect in hormonal regulation of cell function and differentiation. The clarity of how
widespread this regulation is among tissues and species remains unknown because it has only
been described in a limited number of species. In order to establish the importance and
prevalence of the estrogen regulation mechanisms, information on estrogen regulation of serum
proteins from species representing different vertebrates groups is needed.
Estrogen has been shown to regulate a few types of proteins, in a wide variety of species.
In Xenopus laevis, estrogen treatment of males has been shown to induce a key regulatory
enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Chen
and Shapiro, 1990). Its induction by estrogen was shown primarily from mRNA in the livers of
males. A few years later, vigilin, a high-density lipoprotein-binding-protein was found in
vertebrate cells (Dodson and Shapiro, 1997). Vigilin, thought to play an important role in RNA
metabolism, is also an estrogen-inducible protein. Another protein was found in teleosts. When
treated with estrogen, plasma calcitonin secretion levels also increase (Suzuki et al., 2003).
Those proteins, however, play a small role compared to the most widely known estrogen
regulated protein, vitellogenin.
In amphibians, estrogen treatment induces synthesis of vitellogenin in both sexes.
Studies have found that along with this induction of vitellogenin, estrogen concomitantly
decreases the quantity of total serum albumin being produced by the liver. Most of these studies
have been performed on Xenopus laevis. Estrogen exposure to male Xenopus down regulates
absolute albumin mRNA levels by more than 95% during the first 4 days following treatment,
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after which albumin mRNA returns to normal levels over the following 12 days (May et al.,
1982; Riegel et al., 1986; Schoenberg et al., 1989). Estrogen has also been studied in Xenopus
with dexamethasone, a steroid required for preservation of albumin mRNA levels in culture. In
only dexamethasone treatment (the absence of estrogen), albumin mRNA declined rapidly.
Estrogen, however can override the effects of dexamethasone treatment (albumin preservation),
and elicit a decline of over 80% in albumin mRNA levels (Jackson and Shapiro, 1986).
Although suspected endocrine disruptors act along an estrogen-pathway, they do not seem to
elicit the same albumin-down regulated estrogen phenomena. Though there are a lack of studies
on amphibians exposed to endocrine disruptors, one study focuses on human and rat models and
found that exposure to polychlorinated biphenyls (PCBs) may in fact lead to an increase in serum
albumin levels due to increased protein synthesis (Borlak et al., 2002). More studies are
necessary to indicate the trend of potential endocrine disruptor induction of albumin, but this
may also prove to be a valuable biomarker in which to evaluate endocrine disruptors. Given that
estrogen down regulation has been demonstrated in frogs and turtles, it may also be useful as a
biomarker for estrogenic action in other species.

Model Organisms

In the following studies, the primary test animal was the eastern tiger salamander,
Ambystoma tigrinum. This particular salamander is especially prevalent in the Midwestern
portion of the United States and on its eastern coast. It is normally between seven and eight and
a quarter inches long with light olive, or yellowish-brown spots on a dark background (Conant
and Collins, 1999). Its spots are highly irregular in distribution and shape, and these are well
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extended down the sides of the abdomen. Males have a slightly longer tail than females. This
salamander is the most widely distributed salamander species in North America, and is one of the
few capable of tolerating the dry conditions of the many regions in which it lives. They cope
with these conditions by living below the ground in hibernation sites. The tiger salamander likes
to congregate in deep water, and is a winter early spring breeder. The larvae of tiger
salamanders are hatched and live in the water, until maturation, when they develop lungs and
live on land. Because this animal lives in the wild, it is difficult to assess the effects endocrine
disrupting chemicals have on their population. This is why it is critical to study species like the
salamander. The species is consistently declining, and the reason is unknown. There is
speculation of endocrine disrupting chemicals, but this has yet to be proven (Blaustein and
Wake, 1990; Raloff, 1994; Wake, 1991; Carey and Bryant, 1995). Tiger salamander vitellogenin
has never been fully characterized, and was part of the work presented here. Since the
vitellogenin was characterized and analyzed, the salamander can now be used as a model animal
to assess the effects of estrogenic chemicals.
Due to unavailability of tiger salamanders for a final experiment, juvenile spotted
salamanders, Ambystoma maculatum, were used in their place. These salamanders are very
similar to tiger salamanders in their geographic distribution, abundance, and appearance. They
are prevalent along the eastern coastal area and are one of the largest members of the mole
salamander family.
Two other species were also used extensively in this project, Hellbenders,
(Cryptobranchus alleganiensis), and Crocodiles, (Crocodylus moreletii). Serum samples from
both animals were sent to us for analysis. Hellbenders are a type of salamander species also
living in the eastern portion of the United States. Most states where the hellbender is found have
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classified it as an endangered species. The reason for its disappearance remains unknown,
making it a perfect case study for endocrine disruption analysis. Crocodylus moreletii are most
prominent in Central America and are known as a small type of crocodile. These crocodiles
were almost hunted to extinction, and while hunting is now illegal, they are still on the brink of
extinction. Endocrine disruption is also speculated in this species of crocodiles, but this has yet
to be proven.
Hypothesis

Because vitellogenin is presumed to be present in female oviparous vertebrates during the
egg-laying season, the prediction was that female tiger salamanders would also contain
vitellogenin and other estrogen-induced serum proteins during this time. I also predicted that
males would lack vitellogenin but, after estrogen injections, would also produce the vitellogenin
and other serum proteins. This abnormality could then serve as an assay to determine exposure
to estrogenic compounds. It was also proposed that environmental estrogens would induce
vitellogenin and other serum protein production in males and increase its production in females.
There are three specific aims that were addressed in this proposal:
1. To characterize the changes in serum proteins associated with estrogen exposure. This
was achieved by treating immature animals and adult males and females with estrogen. Serum
proteins were evaluated for differences between control and estrogen-treated individuals.
2. To develop immunoassays for detecting changes in vitellogenin and perhaps other
proteins for the future use in studies of endocrine disruption. This entailed developing an
antibody specific for the protein of interest, and developing specific immunoassays.
3. To employ the above-mentioned assays to evaluate responses to specific endocrinedisrupting chemicals.
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Materials and Methods

Chemicals

17β-estradiol and ethinyl-estradiol were purchased from Sigma-Aldrich Corporation (St.
Louis, MO). Aroclor 1221 and Atrazine were purchased from Chem Service (West Chester,
PA). These chemicals were certified standard grade.

Animals

Immature and adult male and female Ambystoma tigrinum were purchased from the
Charles D. Sullivan Company, Inc. (Nashville, TN) and from the William A. Lemberger
Company (Oshkosh, WI). The terrestrial salamanders were housed at room temperature in
plastic aquaria with autoclaved foam pieces and water purified via reverse osmosis. They were
fed Salamander Bites (HBH Enterprises, Inc., Utah) ad libitum. Some salamanders were
subjected to estrogen treatment, others received vehicle alone, and some were subjected to the
xenobiotic (endocrine disrupting chemical) treatments. Salamanders were anesthetized
(ketamine 80mg/kg), and decapitated at the termination of the experiment, and blood was
collected. Blood was allowed to clot for four-hours (h) at room temperature, and serum was
prepared by centrifugation at 2,500 x g for 10 minutes, twice. Serum was stored at –20° Celsius
(C).
Various amphibian samples were sent to us to be screened for vitellogenin. Male
hellbenders samples were sent by J.C. Elrod and Y.W. Huang of the University of MissouriRolla, Rolla, MO. Male and female wild-caught crocodile sera from Belize was taken by T.R.
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Rainwater and S.T. McMurry of Texas Tech University, Lubbock, TX. J. Bettaso and B. Palmer
sent wild caught Rana aurora samples from coastal northern California from Humboldt and Del
Norte Counties.
Experimental design

The experimental design was adapted from Palmer et al., (1998). Estrogens or xenobiotic
estrogens were administered by intraperitoneal injection (i.p.), in order to evaluate estrogenic
responses. Salamanders were injected with 17β-estradiol or ethinyl-estradiol dissolved in
propylene glycol. The injection schedules are listed in the description of each experiment.
During the course of each experiment, all animals were housed in the Duquesne
University Animal Care Facility using approved IACUC Animal Care Protocols submitted to the
Dean.

Experiment 1: 17β-estradiol Injection of Male Ambystoma tigrinum
Twenty male aquatic salamanders were injected with a solution of 0.5 mg/ml 17βestradiol stock solution or a vehicle solution of peanut oil (5-no injection, 5-vehicle injection, 10estrogen injection, see Table 1). Five salamanders were housed together in the cold room (4°C)
in each of four plastic Tupperware boxes in aged tap water purified via reverse osmosis due to
retailer suggestions. The 0.5 mg/ml stock solution was prepared by dissolving 0.200 grams of
17β-estradiol into 20 ml of a 100% ethanol solution. The mixture was stirred well until all of the
17β-estradiol was dissolved. Forty ml of peanut oil (used as a vehicle to deliver the 17βestradiol) was stirred in to create an emulsion. The heat was turned on slowly to boil away all of
the ethanol creating a 0.5 mg/ml stock solution. The vehicle treatment contained only peanut oil.

21

There was 200 µl of solution delivered to each salamander during injection. The tanks were
cleaned and water was changed every three days. Due to the low metabolic rate by living in the
cold, the salamanders were not fed during the course of the experiment. The injection schedule
was as follows is shown in Table 1.
Table 1: Injection Schedule for Experiment 1

Injection Number Day Number
Day 1
1
Day 3
2
3
4
5
6
7

Day 7
Day 11
Day 15
Day 19
Day 23
Day 27

Termination
Arrival Date
Friday May 24th: 5 initial controls which received NO
injections

Thursday June 20th: All remaining salamanders, 5 vehicle
treated, 10 estrogen treated

Experiment 2: Ethinyl-estradiol Injection of Male and Female Ambystoma tigrinum

Nine female and twenty male terrestrial salamanders were injected with various doses of
ethinyl-estradiol stock solution or vehicle solution of propylene glycol (see table 2). Four or five
salamanders were housed together at room temperature in each of eight plastic Tupperware
boxes with minimal aged tap water purified using reverse osmosis. The stock solutions were
prepared by dissolving 60 mg of ethinyl-estradiol into 6 ml of a 100% acetone solution. The
mixture was stirred well until all of the ethinyl-estradiol was dissolved. This solution was then
serially diluted by taking out 600 ml, placing this into the medium dose, taking 600 ml of the
new medium dose and placing that into the low dose. Of the three-doses, 4.5 ml was taken out
from each, and put into three separate 45 ml solutions of propylene glycol (used as a vehicle to
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deliver the ethinyl-estradiol) to create an emulsion. The vehicle solution was made by adding
4.5 ml acetone to 45 ml of propylene glycol. For two days, these four solutions were dried with
a nitrogen-gas stream for 30 minutes, and allowed to evaporate in the hood overnight for two
nights to remove the acetone. The final stock solutions were 0 mg/ml, 0.01 mg/ml, 0.1 mg/ml,
and 1 mg/ml. There was 0.25 mg of solution delivered to each salamander during injection. The
tanks were cleaned and water was changed every three days. The salamanders were fed
salamander bites the day before their tanks were cleaned each time. The injection groups are
shown in Table 2.
Table 2: Injection Regimen for Experiment 2

Sex
Female
Female
Male
Male
Male
Male
Male
Male

Number in Group
5
4
5
4
5
5
4
4

Injection
Once
Once
Once
Once
Every 3rd-day
Every 3rd-day
Every 3rd-day
Every 3rd-day

Estrogen or Control
Estrogen
Control
Estrogen
Control
Estrogen
Estrogen
Estrogen
Control

Dosage
High (1mg/ml)
Vehicle (0mg/ml)
High (1mg/ml)
Vehicle (0mg/ml)
High (1mg/ml)
Medium (0.1mg/ml)
Low (0.01mg/ml)
Vehicle (0mg/ml)

The injection schedule is shown in Table 3.
Table 3: Injection Schedule for Experiment 2

Injection Number Day Number
Day 1
1
Day 10
2
Day 14
3
Day 18
4
Day 22
5
Day 26
6
Day 30
7
Day 34
8
Day 38
Day 41

Termination
Arrival Date
Once injected salamanders were all terminated

All remaining salamanders
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Experiment 3: Ethinyl-estradiol Injection of Juveniles Ambystoma tigrinum

Twenty juvenile terrestrial salamanders (not sexed) were injected with a high dose (1
mg/ml) ethinyl-estradiol stock solution or vehicle (0 mg/ml) solution of propylene glycol (4vehicle injection and 16-estrogen injection). Four salamanders were housed together at room
temperature in each of five plastic Tupperware boxes with minimal aged tap water purified using
reverse osmosis. The stock solutions were used from experiment 2 (0 mg/ml, and 1 mg/ml).
There was 0.20 mg of solution delivered to each salamander during injection. The tanks were
cleaned and water was changed every three days. The salamanders were fed salamander bites
the day before their tanks were cleaned each time. Each salamander received three weekly
injections (each Wednesday). The injection schedule is shown in Table 4.
Table 4: Injection Schedule for Experiment 3

Injection Number Day Number
Day 1
1
Day 2
2
Day 9
3
Day 16
Day 23

Termination
Arrival Date

Terminated all remaining salamanders

Experiment 4: Ethinyl-estradiol Injection and Endocrine Disrupting Chemicals of
Juvenile Ambystoma maculatum

Twenty-two juvenile terrestrial salamanders (not sexed) were injected with high dose (1
mg/ml) ethinyl-estradiol stock solution or vehicle (0 mg/ml) solution of propylene glycol (5vehicle injection and 17-estrogen injection). Twenty-four juvenile terrestrial salamanders (not
sexed) were injected with Aroclor 1221 or Atrazine (6-high dose Aroclor 1221, 6-low dose
Aroclor 1221, 6-high dose Atrazine, 6-low dose Atrazine). Five or six salamanders were housed
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together at room temperature in each of eight plastic Tupperware boxes with minimal aged tap
water purified using reverse osmosis. All stock solutions were made fresh. The ethinyl-estradiol
stock solutions were made by adding 1 ml 100% acetone to 50 ml of propylene glycol (used as a
vehicle to deliver the ethinyl-estradiol) along with 50 mg ethinyl-estradiol. The mixture was
stirred well until all of the ethinyl-estradiol was dissolved. The vehicle solution was made by
adding 1 ml acetone to 50 ml of propylene glycol. The Aroclor 1221 high dose solution was
made by adding 1ml acetone to 50 ml of propylene glycol along with 250 mg Aroclor 1221. The
Aroclor 1221 low dose solution was made by adding 1 ml acetone to 50 ml of propylene glycol
along with 5 mg Aroclor 1221. The Atrazine high dose solution was made by adding 6ml
acetone (due to the solubility of atrazine) to 50 ml of propylene glycol along with 250 mg
Atrazine. The Atrazine low dose solution was made by adding 1ml acetone to 50 ml of propylene
glycol along with 5 mg Atrazine. These solutions were stirred with heat for two days, and
allowed to evaporate in the hood overnight to evaporate away the acetone. The final stock
solutions of ethinyl-estradiol were 0 mg/ml and 1 mg/ml. The tanks were cleaned and water was
changed every three days. The salamanders were fed salamander chow the day before their tanks
were cleaned each time. Each salamander received weekly injections (either Tuesday or
Wednesday) of 0.1 cc per injection. The injection groups are shown in Table 5.
Table 5: Injection Regimen for Experiment 4

Number in Group
5
5
5
6
6
6
6
6
6

Injection
None
Weekly
Weekly
Weekly
Weekly
Weekly
Weekly
Weekly
Weekly

Estrogen or Control
Initial Controls
Control
Estrogen
Estrogen
Estrogen
Aroclor 1221
Aroclor 1221
Atrazine
Atrazine
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Dosage
None
Vehicle (0mg/ml)
High (1mg/ml)
High (1mg/ml)
High (1mg/ml)
Low (0.5mg/ml)
High (5mg/ml)
Low (0.5mg/ml)
High (5mg/ml)

The injection schedule is listed in Table 6 (estrogen and vehicle were injected on Tuesdays while
Atrazine and Aroclor 1221 were injected on Wednesdays).

Table 6: Injection Schedule for Experiment 4

Injection Number Day Number
Day 1
Day 5
1
Day 9
Day 10
2
Day 16
Day 17
3
Day 23
Day 24
Day 26

Termination
Arrival Date
5 Initial controls which received NO injections

Terminated all remaining salamanders

Hellbender Experiment (Cryptobranchus alleganiensis)

Blood was taken from two male hellbenders by J.C. Elrod and Y.W. Huang of the
University of Missouri-Rolla, Rolla, MO prior to estrogen-injection to establish control values
for each animal. They were then injected intraperitonally (with a concentration of 2.5mg/kg
body weight of 17-β estradiol dissolved in ethanol), and blood was taken 7 days after this first
injection for a first reading. The hellbenders were then injected with the same dose of estrogen
again, and 7 days after this injection, blood was taken for a second reading. After blood was
collected it was placed into heparinized vaccutainers and spun down by centrifugation. Plasma
was then collected, put into cryovials, and placed on liquid nitrogen (–170° C) for storage.
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Crocodile Experiment (Crocodylus moreletii)

Male and female crocodile sera was taken by T.R. Rainwater and S.T. McMurry of Texas
Tech University, Lubbock, TX, and were used to test for the presence of vitellogenin in wildcaught crocodiles from Belize.

Rana aurora Experiment

A number of wild caught Rana aurora samples (13 females, 3 non-distinguishable of sex,
81 sub-adults (juveniles), and 58 males) from coastal northern California from Humboldt and
Del Norte Counties were taken by J. Bettaso and B. Palmer to be screened for vitellogenin.

Purification of Ambystoma vitellogenin

Ambystoma tigrinum serum was fractionated using a diethylaminoethyl (DEAE)
chromatography procedure that was used previously and found effective for purification of turtle,
and frog vitellogenins (Selcer and Palmer, 1995; Palmer et al., 1998). The procedure was run on
a BioRad Econo Chromatography system (BioRad, Melville, NY, USA) using a DEAE-agarose
column (1.0 X 15 cm). The equilibration buffer was 25 mM tris (hydroxymethyl) aminomethane
(Tris)-HCl, with 1 mM monothyioglycerol, pH 7.5. The gradient buffer was 500 mM NaCl in
equilibration buffer. Pooled sera from 17β- or ethinyl-estradiol-treated individuals totaling 100
µl was diluted 1:10 v/v in equilibration buffer and loaded onto the column. The column was
washed with 30 ml equilibration buffer to remove proteins that did not adhere to the DEAE.
Proteins were eluted using a linear gradient of NaCl (0 to 500 mM NaCl). A total volume of 90
ml was used. Protein was monitored by ultraviolet absorbance at 280 nm throughout the
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chromatography run. Fractions of 3 ml were collected throughout the procedure. Protein levels
were determined separately for each fraction by a Coomassie protein assay. Fractions containing
significant amounts of protein were evaluated for the presence of vitellogenin by denaturing gel
electrophoresis. DEAE fractions found to contain vitellogenin, a 200kDa protein, were then
pooled and dialyzed against DEAE equilibration buffer overnight using Spectra/Por 1 dialysis
membrane (Spectrum, Houston, TX, USA). After dialysis, the fractions were run again on the
DEAE column under the same conditions as used for the serum. The resulting vitellogenincontaining fractions were pooled, dialyzed against water, and lyophilized under a vacuum. The
purified vitellogenin was stored in the –20°C until further use.

Protein Gel for Sequencing

The gel was run according to the gel electrophoresis and the immunoblotting protocol,
with adaptations as noted. The samples used for the gel were the serum salamander estrogentreated samples. Directly after the gel was run, it was put into the western apparatus for
acclimation and the western was run using Immobilon-PSQ PVDF transfer membrane (Millipore,
Bedford, MA). After the western ended, the membrane was placed in nanopure water for 5 – 10
minutes changing the water three times. The membrane was then placed in a 20% methanol
solution for 5 – 10 minutes, followed by a 50% methanol solution for 5 – 10 minutes. Lastly, the
membrane was placed in a 100% methanol solution for only a few seconds. Stain (0.025%
Coomassie Blue R-250 in 40% methanol) was then applied for approximately 45 seconds (at a
maximum). The membrane was then destained (50% methanol) three times (approximately 5
minutes each time). The bands were cut out while they were still wet and the membrane was
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dried for approximately 30 minutes. The bands and membrane were put in the –20°C freezer and
sent to ProSeq, Inc. (Boxford, MA) for sequencing.

Polyclonal antibody production

The N-terminal amino acid sequence of salamander, hellbender, and crocodile
vitellogenin was determined and sent to Invitrogen (Carlsbad, CA) for antibody production.
Polyclonal antibodies against purified Ambystoma tigrinum vitellogenin were generated in
rabbits. Rabbits were immunized initially with DEAE-purified vitellogenin (500 µg) in Freund’s
complete adjuvant. Injections of emulsified vitellogenin in adjuvant were made subcutaneously
in eight different sites using approximately 0.1 ml per injection site. Booster immunizations
were given at 30-d intervals after the initial immunization. This procedure for booster injections
was the same as for the initial injection; except that Freund’s incomplete adjuvant was used.
Bleeding was performed prior to the initial immunization (test bleed) and 10 d after each
immunization. Twenty ml of blood was taken from the marginal ear vein and allowed to clot at
room temperature for 4 h. Serum was then prepared by centrifugation. Serum was stored at
–20°C until use.

Coomassie Protein Assay

BSA was used as the protein standard for protein determination (stored at –20° C). The
protein concentration was determined by the methods of the Bradford assay (Bradford, 1976).
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The Coomassie stain was made by dissolving 100 mg Coomassie Blue G-250 (available
from several sources) in 50 ml 95% ethanol, adding 100 ml 85% (w/v) phosphoric acid to this
solution and diluting the mixture to 1 liter with water.
A series of protein dilutions were prepared in duplicate. For serum, between 2 and 5 µg
and 1998 – 1995 µl of nanopure water showed the closest range to the standard curve; for
cytosol, between 10 – 13 µg and 1990 – 1982 µg of nanopure water showed the closest range to
the standard curve. This mixture was put into 13 X 100 Eppendorf tubes. Two ml of the
Coomassie stain was added to each tube so that the final tube volume was 4 ml. The tubes were
vortexed and allowed to stand for five minutes. In this time the Spectronic 20 spectrophotometer
was warmed up and blanked with a tube containing 2 ml of nanopure water and 2 ml of
Coomassie stain. The absorbencies of the sample tubes were read at 620 nm, and plotted against
the standard curve. The protein concentration of each tube was determined using the standard
curve to find the concentration of standard that would have the same absorbance as the sample.

Gel Electrophoresis

Ambystoma tigrinum sera and DEAE fractions were electrophoresed under denaturing
conditions in polyacrylamide gels using sodium dodecysulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). BioRad precast 4-15% gradient gels were used. Proteincontaining samples (DEAE fractions or serum, diluted appropriately) were mixed 1:1 v/v with
Laemmli sample buffer (5% w/v 2-mercaptoethanol, 2.3%SDS, 62.4 mM Tris-HCl, pH 6.7,
0.02% w/v bromophenol blue, 10% w/v glycerol) and denatured by heating for 4 min in a boiling
water bath. Wide range SigmaMarker standards were used in all SDS-PAGE gels. The proteins
and their molecular weights in the marker are as follows: Myosin, rabbit muscle 205,000; β-
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Galactosidase, E.coli 116,000; Phosphorylase b, rabbit muscle 97,000; Fructose-6-phosphate
Kinase, rabbit muscle 84,000; Albumin, bovine serum 66,000; Glutamic Dehydrogenase, bovine
liver 55,000; Ovalbumin, chicken egg 45,000; Glyceraldehyde-3-phosphate Dehydrogenase,
rabbit muscle 36,000; Carbonic Anhydrase, bovine erythrocytes 29,000; Trypsinogen, bovine
pancreas 24,000; Trypsin Inhibitor, soybean 20,000; _-Lactalbumin, bovine milk 14,200;
Aprotinin, bovine lung 6,500 (Sigma Aldrich, Saint Louis, MO). Samples were run at a constant
current of 20 mA at room temperature until the dye front reached the bottom of the gels. Gels
were stained with Coomassie dye or were used for immunoblotting.

Immunoblotting

Proteins separated by SDS-PAGE were transferred to polyvinylidene fluoride (PVDF)
membranes (BioRad) for immunoblotting. Kaleidoscope Prestained Standards were used in all
SDS-PAGE gels for immunoblotting. The proteins and their molecular weights in the marker are
as follows: Myosin 210,000; β-Galactosidase 135,000; Bovine serum albumin 82,000; Carbonic
anhydrase 38,700; Soybean trypsin inhibitor 31,900; Lysozyme 18,100; Aprotinin 7,400 (BioRad
Laboratories, Hercules, CA). Transfers were performed in a BioRad Trans-Blot apparatus
packed in ice, at 70V for 3 h at 4°C. The transfer buffer contained 25 mM Tris, 192 mM glycine,
20% methanol, 10 ml SDS, pH 8.3. After transfer, the PVDF membrane was incubated
(blocked) in 5% nonfat dry milk for 1h at room temperature, with shaking. This solution was
replaced with 5% nonfat dry milk containing the primary antibody, (rabbit anti-Ambystoma
vitellogenin serum) diluted appropriately, and was incubated for 16 h at room temperature with
shaking. A listing of all potential primary antibodies is listed in Appendix 1. The PVDF
membrane was then washed (15 min, with shaking) once with 50 mM Tris-HCl (pH 7.5), 0.9%
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NaCl, 0.05% Tween-20, and twice with 50 mM Tris-HCl, 0.9% NaCl. The PVDF membrane as
then incubated in 5% nonfat dry milk containing the secondary antibody, (peroxidase-coupled
goat anti-rabbit serum (BioRad), diluted 1:3,000, and was incubated for 2 h at room temperature,
with shaking. The PVDF membrane was again washed once with 50 mM Tris-HCl, 0.9% NaCl,
0.05% Tween-20, and twice with 50 mM Tris-HCl, 0.9% NaCl, and then was developed for 5
min with peroxidase substrate (diaminobenzidine and urea-hydrogen peroxide tablets, Sigma
Chemical) until bands appeared. The reaction was then stopped by pouring the peroxidasesubstrate off and rinsing the PVDF membrane with 50 mM Tris-HCl, 0.9% NaCl.

Native Gel Electrophoresis

Ambystoma tigrinum sera and DEAE fractions were electrophoresed under native (nondenaturing) conditions in polyacrylamide gels using native gel electrophoresis. BioRad precast 4
to 15% gradient gels were used. Protein-containing samples (DEAE fractions or serum, diluted
appropriately) were mixed 1:1 v/v with native sample buffer. Samples were run at 20 mA at
room temperature in sample buffer prepared without SDS, until the dye front reached the bottom
of the gels. Gels were stained with Coomassie dye and were used for immunoblotting (without
using SDS).

Periodic Acid Schiffs Test

In order to detect glycoproteins, a procedure was adapted from Covens et al., (1988).
After performing the gel electrophoresis as usual, the gel was fixed overnight in a solution of
methanol: acetic acid: water (50:7:43). The following day, oxidation of carbohydrate moieties in
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periodic acid and sodium acetate (1%/1.6% v/w) was performed for 20 h at room temperature on
a shaker. The third day, the gel was incubated in undiluted Schiffs reagent for electrophoresis
for 1 h at 4°C in the dark on the shaker. The gel was destained in a freshly prepared solution of
5% N2S2O5 in 1 N HCl for 15-30 min. The background staining was further decreased in a 10%
acetic acid solution.

Enzyme-linked Immunosorbent Assay (ELISA)

Serum samples were diluted with phosphate-buffered saline (PBS) (136 mM NaCl, 1.5
mM KH2PO4, 8.2 mM Na2HPO4, 2.7 mM KCl, pH 7.2), and 100 µl was added to the individual
wells of a polystyrene microtiter plate. Phosphate-buffered saline alone was added to wells
designated as blanks. Antigen was allowed to bind to the plates overnight at 4° C in a covered
glass dish with water to create a humidity chamber. The plate was then washed four times with
PBS. Next, 200 µl PBS-blotto (5 g nonfat dry milk in 100 ml PBS) was used to block for 1 h at
room temperature, covered, with shaking. The PBS-blotto was replaced with 100 µl of PBSblotto containing primary antibody (rabbit anti-Ambystoma vitellogenin serum) and the plate was
incubated covered for 2 h on the shaker at room temperature. A listing of all potential primary
antibodies is listed in Appendix 1. The plate was then washed four times with PBS and
incubated covered for 2 h on the shaker at room temperature, with the secondary antibody, (goat
anti-rabbit immunoglobulin conjugated to horseradish peroxidase (BioRad)) diluted 1:1,000 in
PBS-blotto. The plate was then washed four times with PBS, then developed using a TMB
Peroxidase EIA Substrate Kit (BioRad) and then incubated for 5 min at room temperature.
Absorbance’s of the wells was read by a BioRad model 3550 microplate reader at 650 nm at 5
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min at room temperature and at 10 min. The reaction was stopped with 1 N H2SO4 and the
absorbencies were read at 450 nm with background subtraction at 650 nm.

Liver Homogenization Protocol: Preparation of Salamander Liver Cytosol

The low-, mid-, and high-speed centrifuges were chilled to 4° C. Livers were obtained
from storage in the –80° C refrigerator and kept on dry ice. The entire liver (contents of
approximately 0.3 g), were weighed out and their exact weight recorded. The livers were placed
into 10ml beakers, to which 4.5 ml of buffer TE (composed of 50 ml Tris Stock (1 M) and 10 ml
of EDTA Stock (0.1 M) brought up to 1 L with nanopure water) was added at a ratio of 1:15
g/ml. The liver mixture was finely diced using scissors and a tissue terror each three times at 10
seconds apiece. This mixture was placed into 15 ml conical tubes, which were centrifuged at
2500 X g for 10 minutes at 4° C in the low-speed centrifuge. The supernanent was placed into
Corex tubes with a heavy plastic holder. These were then centrifuged at 9200 RPM for 30
minutes at 4° C in the mid-speed centrifuge. The supernanent was then placed into Beckman
tubes and centrifuged at 31,200 RPM for 1 h at 4° C in the high-speed centrifuge. The
supernanent was taken and placed into the –20° C freezer until further analysis.

Statistical Analysis

Various treatment groups were compared by Student’s T-Test and one-way analysis of
variance (ANOVA) with repeated measures. The statistical program used was Prism (GraphPad,
Inc., San Diego, CA). Data are presented in the results as the Mean +/- 1 SEM (Standard Error
of the Mean). Densitometry was conducted using the National Institute of Health program NIH
Image Version 1.61. A sample of densitometry plots is illustrated in Appendix 8.
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Results
Experiment 1: 17β-estradiol Injection of Male Ambystoma tigrinum

Estrogen treatment significantly reduced the body weight of the salamanders. The mean
body weight of the vehicle salamanders was 173.9 g +/- 7.887. The mean body weight of the
estrogen-treated salamanders was 152.1 g +/- 4.613. A t-test showed this difference to be
significant (t = 2.56; 13 df; p < 0.05). Data are from fifteen salamander samples (five vehiclecontrols, and ten estrogen-treated). Appendix 2 shows the final weights of each salamander.
Mean serum protein concentration was significantly increased for the estrogen-treated
group compared with the vehicle-control group, indicating that estrogen treatment was associated
with an increase in total serum protein concentration. The mean serum protein concentration for
the control salamanders was 20.03 µg/µl +/- 2.66 while the mean for the estrogen-treated
salamanders was 38.40 µg/µl +/- 3.99. The significance was demonstrated by a t-test (t = 3.044;
13 df; p < 0.01). Appendix 3 shows the total protein concentrations for each salamander.
Differences between 17β-estradiol-treated and untreated males were examined for
salamander liver cytosol using SDS-PAGE (Figure 1). No obvious differences were observed
between the experimental and control groups. There was no indication of a 200-kDa protein (the
expected size of vitellogenin) in either group.
Differences between 17β-estradiol-treated and untreated males were also examined for
salamander serum using SDS-PAGE (Figure 2). A 66-kDa protein appeared to decrease upon
exposure to estrogen. Although the amounts of albumin were depressed in the estrogen-treated
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salamanders as compared to the control group, the results of a t-test (t = 1.509; 8 df; p > 0.05)
determined that there is no statistical significance between the two groups when using
densitometry. There was no indication of the presence of a 200-kDa protein (the expected size
of vitellogenin) in either group.
Native PAGE was run to evaluate differences in serum proteins under non-denaturing
conditions (Figure 3). No clear differences were observed between the experimental and control
salamanders sera.

Experiment 2: Ethinyl-estradiol Injection of Ambystoma tigrinum

Single Injection, Males and Females

Mean serum protein concentration was not significantly different between the estrogentreated group and the vehicle-control group. The mean value for the control salamanders was
29.90 µg/µl +/- 6.005 while the estrogen-treated salamanders was 30.74 µg/µl +/- 2.739. No
significant difference was found by a t-test (t = 0.1275; 6 df; p > 0.05). Data shown are
representative of eight salamander samples (after ten deaths due to red-legged disease).
Appendix 4 shows the total protein concentrations for each salamander.
SDS-PAGE was used to evaluate the differences between ethinyl-estradiol singleinjection-treated and untreated male and female sera. Both estrogen-treated male and female
salamanders revealed the presence of a 200kDa protein (the expected size of vitellogenin)
(Figure 4). This protein was not evident in untreated male and female sera and was determined
to be statistically increased in the estrogen-treated groups as compared to the controls by
densitometry readings (t = 2.436; 6 df; p < 0.05).
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Multiple Injection, Males

Mean serum protein concentration was reduced for the estrogen-treated group compared
with the vehicle-control group. The mean value for the control salamanders was 30.39 µg/µl +/3.94 while that for the high dose estrogen-treated salamanders was 21.72 µg/µl +/- 3.39. These
values were not significantly different, as demonstrated by a t-test (t = 1.668; 4 df; p > 0.05).
Data shown are representative of six salamander samples (after four deaths due to red-legged
disease). Appendix 5 shows the total protein concentrations for each salamander.
SDS-PAGE was used to examine differences in cytosol between multi-injected ethinylestradiol-treated and untreated males. There were no obvious differences seen between the high,
low, and control groups. There was no evidence of a 200kDa protein (the expected size of
vitellogenin) on SDS-PAGE (Figure 5).
SDS-PAGE was also used to assess differences in serum proteins between ethinylestradiol multi-injection-treated and untreated males (Figure 6). A 66kDa protein appeared to
decrease upon exposure to estrogen, however, again the results of a t-test (t = 1.225; 6 df; p >
0.05) determined that there was no statistical significance between the two groups using
densitometry. Also, high and low dose ethinyl-estradiol-treated salamanders contained high
levels of a 200kDa protein (the size of the protein vitellogenin). This protein was not present in
the control serum samples. A periodic acid Schiff’s test for glycoproteins was inconclusive as to
whether there were glycoproteins present or not (Figure not shown).
An SDS-PAGE gel was run and transferred to a PVDF membrane for use in N-terminal
amino acid sequencing. The blot was sent off to ProSeq, Inc. (Boxford, MA) for sequencing of
the salamander presumptive vitellogenin. The first sequence obtained was
“(S)QYN(S)E(S)VF(S)()(A)”. The letters represented in parenthesis are the most likely amino
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acids, but they cannot be deemed conclusive. Since this result did not seem very accurate, we
had them re-sequence the amino acids, and determined from the two that the more confident
sequence was the following: “CQYNHEPVFSESKSY(V)YN(Y)(E)A(L)I”. The result was a
sequence closely resembling the Xenopus vitellogenin N-terminal sequence (Table 7).

Table 7: Comparison of the N-Terminal Amino Acid Sequences of Vitellogenin Proteins in Amphibians

X. laevisa

EPVFSESKTSVYNYEAVI

A. tigrinum

CQYNHEPVFSESKSYVYNYEALI

C. alleganiensis

EQYNYEPVFSEIKTYVYNYEA

Black = Identical
Pink = Conserved
Blue = Different
a

Sequence from Genbank Accession No. X01168.1.

DEAE chromatography was performed on sera from ethinyl-estradiol multi-injectiontreated and untreated males to further evaluate protein differences (Figures 7, 8, 9, 10). Three
distinct peaks were evident in fractions from the DEAE column. The first peak eluted during the
wash and represented proteins that did not adhere to the column. The second and third peaks
eluted during the salt gradient, with peak two at low salt and peak three at high salt. Analysis of
the peaks by SDS-PAGE revealed that the second peak consisted largely of proteins in the
70kDa range, probably representing albumin. This peak was consistently larger for control sera
as compared to estrogen-treated sera. Densitometry showed the control proteins to be more
abundant than the estrogen treated proteins. Statistics could not be run between fractions, since
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only one serum sample was used for estrogen and control profiles. The third peak contained
abundant amounts of a 200kDa protein. This protein was presumed to be vitellogenin, because it
had the appropriate molecular weight for Xenopus laevis vitellogenin and because vitellogenin is
known to elute at high salt from DEAE. Also, the 200kDa protein was present in DEAE
fractions from estrogen-treated salamander sera but was absent in the corresponding fractions
from control salamander sera, indicating that it was estrogen-induced.

Experiment 3: Ethinyl-estradiol Injection of Juvenile Ambystoma tigrinum

Estrogen treatment had no significant effect on the body weight of the experimental
salamanders. The mean body weight of the vehicle salamanders was 7.427 g +/- 0.009. The
mean body weight of the estrogen-treated salamanders were 6.753 g +/- 0.2404. A t-test showed
this difference was not significant (t = 1.362; 13 df; p > 0.05).

Data shown are representative of

fifteen (three controls and twelve ethinyl-estradiol treated) salamander samples after deaths (one
vehicle and four ethinyl-estradiol treated) due to red-legged disease. Appendix 6 shows the final
weights of each salamander.
SDS-PAGE was used to examine differences between ethinyl-estradiol-treated and
untreated juveniles liver cytosol (Figure 11). There were no obvious differences observed
between the experimental and control groups. There was no evidence of a 200kDa protein (the
expected size of vitellogenin).
SDS-PAGE was also used to evaluate the differences between ethinyl-estradiol-treated
and untreated juvenile sera. A 66kDa protein appeared to decrease upon exposure to estrogen,
and this difference was statistically significant when evaluated by densitometry (t = 2.781; 13 df;
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p < 0.05). The sera of ethinyl-estradiol salamanders contained high levels of a 200kDa protein
(the size of the protein vitellogenin) on SDS-PAGE (Figure 12). This protein resembling
vitellogenin was not present in the control samples of salamander serum, and was shown to be
significantly higher when evaluated by densitometry (t = 4.035; 13 df; p < 0.01).
A native PAGE was run to evaluate adult and juvenile samples in their non-denatured
form (salamanders from Experiments 2 and 3). No clear differences were evident between the
experimental and control salamanders (Figure 13).
DEAE chromatography was performed to further evaluate the differences in serum
proteins for juveniles (Figure not shown). Three distinct peaks were evident in fractions for the
DEAE column. The first peak eluted during the wash and represented proteins that did not
adhere to the column. The second and third peaks eluted during the salt gradient with the second
peak at low salt and the third at high salt. Analysis of the peaks by SDS-PAGE revealed that the
second peak consisted largely of proteins in the 70kDa range, presumably albumin. This peak
was consistently larger for control sera as compared to estrogen-treated sera. The third peak
contained abundant amounts of a 200kDa protein. This protein was presumed to be vitellogenin,
because it had the appropriate molecular weight for Xenopus laevis vitellogenin, and because
vitellogenin is known to elute at high salt from DEAE. Also, the 200kDa protein was present in
DEAE fractions from estrogen-treated salamander sera but was absent in the corresponding
fractions from control salamander sera, indicating that it was estrogen-induced.
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Experiment 4: Ethinyl-estradiol Injection and Endocrine Disrupting Chemicals
of Juvenile Ambystoma maculatum
Ethinyl-Estradiol Treatment

Estrogen treatment apparently increased the body weight of the salamanders. The mean
body weight of the vehicle salamanders was 12.07 g +/- 0.7602. The mean body weight of the
estrogen-treated salamanders were 13.08 g +/- 0.4126. An ANOVA showed no significant
differences between the groups for body weight (F = 0.2901; 3, 35 df; p > 0.05). The groups
included in the ANOVA were vehicle salamanders, estrogen-treated salamander, atrazine-treated
salamanders, and aroclor 1221-treated salamanders. Data shown are representative of sixteen
(seven controls and nine ethinyl-estradiol treated), after deaths (three vehicle, eight ethinylestradiol treated) due to natural causes. Appendix 7 shows the final weights of each salamander.
SDS-PAGE was used to examine differences between ethinyl-estradiol-treated and
untreated sera. A 66kDa protein appeared to decrease upon exposure to estrogen, however this
difference was not statistically significant using densitometry (F = 1.164; 4, 33 df; p > 0.05)
(Figure 14). The sera of ethinyl-estradiol-treated salamanders contained high levels of a 200kDa
protein on SDS-PAGE (the expected size of vitellogenin). This protein, resembling vitellogenin,
was not present in control salamander sera, and the increase was shown to be statistically
significant by a densitometry (t = 6.467; 14 df; p < 0.0001).
Atrazine Injection

Atrazine exposure had no apparent effect on the body weight of salamanders. The mean
body weight of the vehicle salamander was 12.07 g +/- 0.76. The mean body weight of the highand low-dose atrazine-treated salamanders was 12.63 g +/- 0.95. Again, the ANOVA showed no
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significant differences between the groups (data shown above). Data shown are representative of
eight atrazine (six low dose and two high dose) salamander samples after deaths (four atrazine
high dose treated) due to natural causes (same controls as previous). Appendix 6 shows the final
weights of each salamander.
SDS-PAGE was used to examine the differences between atrazine-treated and untreated
sera. A 66kDa protein appeared to decrease upon exposure to atrazine, however the difference
was not statistically significant using densitometry (F = 1.164; 4, 33 df; p > 0.05) (Figure 15).
The atrazine serum samples did not show the presence of the 200kDa protein (the expected size
of vitellogenin).
Aroclor 1221 Injection

Aroclor exposure also had no apparent effect on the body weight of salamanders. The
Aroclor high-dose exposure appeared to initiate a slight decrease in the body weight of the
salamanders, while the low-dose exposure increased salamander body weight. The mean body
weight of the vehicle salamander was 12.07 g +/- 0.76. The mean body weight of the high- and
low-dose Aroclor-treated salamanders was 12.36 g +/- 0.79. Again, the ANOVA showed no
significant differences between the groups (data shown above). Data shown are representative of
12 salamander samples (6 aroclor 1221 high dose, 6 aroclor 1221 low dose). Appendix 6 shows
the final weights of each salamander.
SDS-PAGE was used to evaluate the differences between Aroclor 1221-treated and
untreated sera. A 66kDa protein appeared to decrease upon exposure to Aroclor 1221, however
this difference was not statistically significant using densitometry (F = 1.164; 4, 33 df; p > 0.05)
(Figure 16). The Aroclor 1221 serum samples did not show the presence of the 200kDa protein
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visually (the expected size of vitellogenin) on SDS-PAGE, these samples did appear to show
weak bands in the 200kDa protein range when evaluated using densitometry.

Hellbender Experiment (Cryptobranchus alleganiensis)
SDS-PAGE was used to evaluate the differences between 17-β estradiol-treated and preinjection male sera. A 66kDa protein appeared to decrease upon exposure to estrogen (Figure
17). This protein appeared to be depressed in the first injection samples as compared with
controls, and was even more depressed in the second injection animals. The sample sizes were
not large enough to run statistics. The treated hellbenders contained high levels of a 200kDa
protein (the expected size of vitellogenin). This protein, resembling vitellogenin, was not present
in the pre-injection samples of hellbender serum. Again the sample sizes were not large enough
to run statistics.
An SDS-PAGE gel was run and transferred to a PVDF membrane to be used for Nterminal amino acid sequencing. The blot was sent off to ProSeq, Inc. (Boxford, MA) for
sequencing of the hellbender presumed vitellogenin. The result was a sequence closely
resembling vitellogenin in Xenopus, and the sequence received for salamanders
(EQYNYEPVFSE(I)KTYVYNYEA) (see Table 7).
DEAE-agarose chromatography was performed to further evaluate differences between
serum proteins of estrogen-treated and pre-treated males. Three distinct peaks were evident in
treated fractions from the DEAE column. The first peak eluted during the wash and represented
proteins that did not adhere to the column. The second and third peaks eluted during the salt
gradient with peak two at low salt and peak three at high salt. Analysis of the peaks by SDS-
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PAGE revealed that the second peak consisted largely of proteins in the 70kDa range,
representing albumin (Figure 18, 19). This peak was consistently larger for control sera as
compared to estrogen-treated sera. Densitometry readings of the peak two fractions showed this
decrease to be significantly different between the experimental and pre-treatment groups (t =
3.440; 6 df; p < 0.05). The third peak contained abundant amounts of a 200kDa protein. This
was presumed to be vitellogenin, because it had the appropriate molecular weight for Xenopus
laevis vitellogenin, and because vitellogenin is known to elute at high salt from DEAE. Also, the
200kDa protein was present in DEAE fractions from estrogen-treated male hellbender sera but
was absent in the corresponding fractions from pre-injection male hellbender sera.

Crocodile Experiment (Crocodylus moreletii)
Male and female crocodile sera were used to test for the presence of vitellogenin in wildcaught crocodiles from Belize. SDS-PAGE revealed the presence of an approximately 200kDa
protein (the size of the protein vitellogenin) in female samples that was absent in male samples
(Figure 20). This protein resembling vitellogenin was not present in the male samples of
crocodile serum, and the difference was shown to be significant when evaluated by densitometry
readings (t = 12.48; 10 df; p < 0.0001). These female samples were pre-selected from all of the
females sampled having the highest estradiol levels, as determined by RIA.
An SDS-PAGE gel was run and transferred to a PVDF membrane to be used for Nterminal amino acid sequencing. The blot was sent off to ProSeq, Inc. (Boxford, MA) for
sequencing of the crocodile presumed vitellogenin. The resulting sequence could not be
determined after two attempts.
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The Western blot using vitellogenin antibody #498 showed cross-reactivity with a protein
of approximately 200kDa in the female sera, and showed no cross-reactivity at all in the male
sera (Figure 21). The Western blot also shows reactivity with a few other bands, at
approximately 77kDa and 64kDa, however, no bands show up in any of the male lanes.
An ELISA was performed using pooled samples to create a titration curve of broadly
cross-reactive antibody #498 in order to find the correct antibody dilution to use when evaluating
crocodile samples (Figure 22). This titration curve illustrated that the samples reacted best
against the 1:1000 dilution. A second ELISA was run using a 1:1000 dilution of broadly crossreactive antibody #498 against all samples. This ELISA showed much greater cross-reactivity
with the female sera than with the male sera, suggesting that wild-caught females contain
vitellogenin whereas the males do not (Figure 23). The mean optical density of the females was
0.7010 +/-0.0469 where the mean of the males was 0.1277 +/- 0.00438. A t-test shows this
difference to be significant (t = 12.17; 22 df; p < 0.0001).
DEAE-agarose chromatography was performed to further evaluate the serum proteins of
male and female crocodiles (Figure 24, 25). Three distinct peaks were evident in fractions from
the DEAE column. The first peak eluted during the wash and represented proteins that did not
adhere to the column. The second and third peaks eluted during the salt gradient with peak two
at low salt and peak three at high salt. Analysis of the peaks by SDS-PAGE revealed that the
second peak consisted largely of proteins in the 70kDa range, resembling albumin. This peak
was consistently larger for control sera as compared to estrogen-treated sera. Densitometry
showed the male peak being larger than the female peak, although statistics could not be run
between fraction numbers. The third peak contained abundant amounts of a 200kDa protein,
presumably vitellogenin, since this protein had the appropriate molecular weight for Xenopus
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laevis vitellogenin and because vitellogenin is known to elute at high salt from DEAE. Although
very light, the 200kDa protein was present in DEAE fractions from female crocodiles sera but
was absent in the corresponding fractions from male crocodile sera, (this difference was clearly
demonstrated in densitometry readings). The densitometry values for these samples are as
follows, for lane 29: female = 813 pixels, male = 481, lane 30: female = 1137 pixels, male = 581
pixels.

Rana aurora Experiment
A number of wild caught Rana aurora samples (13 females, 3 non-distinguishable of sex,
81 sub-adults (juveniles), and 58 males) from California were screened for vitellogenin. An
initial SDS-PAGE analysis was done using five estrogen-treated samples and three wild-caught
(juveniles), revealing the presence of an approximately 200kDa protein (the expected size of
vitellogenin) in both the wild-caught and estrogen-treated Rana aurora samples (Figure 26).
The corresponding Western blot using Rana-anti-vitellogenin-antibody #92 revealed
cross-reactivity against a 200kDa protein in three of the five estrogen-treated samples, but did
not react with anything in the wild-caught samples (Figure 26).
An ELISA using five Rana aurora wild-caught males, five estrogen-injected samples as a
positive control, and a previous Rana aurora male (negative-control) and estrogen-treated
sample (positive control), were evaluated in a screen of antisera from five different rabbits (#498,
#547, #90, #92, and anti-turtle). This was done as a means for assessing which antibody would
be best suited for screening all of the wild-caught Rana aurora samples. The five wild-caught
samples showed no reactivity to any antibody (suggesting that no vitellogenin was present). Out
of the five estrogen-treated samples, two showed no reactivity to any antibody, but the other
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three showed reactivity against antibodies #90 and #92 (Rana), which was comparable to the
reactivity of estrogen-treated serum positive controls against only antibody #90 and #92. The
negative control serum showed no reactivity to any antibody. An ELISA screen of all Rana
aurora wild-caught samples was then evaluated using antibody #92. Only 9 of the 13 female
samples, 2 of the 3 non-distinguishable of the sex, 2 of the 81 sub-adults (juveniles), and 0 of the
58 male samples reacted with the antibody, i.e., most samples in the population were nonvitellogenic (Table 8). Of the total population in the lake, only 13 individuals showed positive
for vitellogenin out of the 155 total members of the population, representing that only 8.39% of
the population are vitellogenic.

Table 8: Vitellogenic Population of Rana aurora from California
Sexual Type

Total Number in Population

Females
Males
Subadults (juveniles, unable to
sex yet, could be males or
females)
Non-distinguishable
TOTAL Population

13
58
81

Number shown positive for
Vitellogenin
9
0
2

3
155

2
13

Polyclonal Antibody Production
Ambystoma tigrinum

In salamander experiment #1, Western blotting, using a rabbit-anti-vitellogenin
antiserum, confirmed that there was no reactivity to any proteins resembling vitellogenin
(approximately 200kDa) (Figure 27). This Western did reveal the reaction of a protein of
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approximately 100kDa with the salamander serum, but because it occurred in both the 17βestradiol-treated and control salamanders, it did not appear to be vitellogenin. However, because
the SDS-PAGE of estrogen-treated samples did not reveal the presence of vitellogenin
(approximately 200kDa), the absence of reactivity was not pursued further (See Figure 2).
In salamander experiment #2, Western blotting with a broadly cross reactive antivitellogenin antiserum (#498) did not reveal cross-reactivity against vitellogenin in the female
sera. It appeared to again react with a 100kDa protein in both male and female sera. The same
antibody was also tested against DEAE fractions and still showed no cross-reactivity for any
fractions (male or female) (Figure 28). A Western blot antibody screen was conducted to assess
cross-reactivity to the 200-kDa protein using samples from estrogen-treated and control male
samples. The only reaction from the sera was the same 100-kDa protein with equal strength to
antibodies #498, #547, #90, and #92, but no reaction was seen at all to anti-turtle antiserum
(Figure 29). There was very little difference between the appearance of the male and female sera
on the Western blot, again suggesting the antibodies did not recognize vitellogenin.
Due to the lack of reactivity in the Western blot, an ELISA was run to attempt to detect
serum vitellogenin. In all cases, the ELISA was inconclusive for male, female, ethinyl-estradioltreated, and control salamanders. However, all estrogen-treated and control samples reacted with
antibodies #498, #547, #90, and #92, but did not react to anti-turtle. This again suggested the
antibodies were not recognizing vitellogenin.
Another ELISA was run to attempt to detect serum vitellogenin from the salamanders in
experiment #3 against antibodies #498, #547, #90, and #92, and anti-turtle antiserum. In all
cases, the ELISA was inconclusive (data not shown).
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Cryptobranchus alleganiensis

Western blotting using a rabbit-anti-vitellogenin antiserum (#498) in hellbenders again
confirmed that there was no reactivity of any proteins resembling vitellogenin (approximately
200kDa) (Figure not shown). A Western blot antibody screen was conducted to assess crossreactivity to the 200-kDa protein using samples from pre-treated and estrogen-treated
hellbenders. The only reaction from the sera was the same 100-kDa protein with equal strength
to antibodies #498, #547, #90, and #92, but no reaction was seen at all to anti-turtle antiserum
(Figure 30).
The lack of reactivity prompted the performance of an ELISA. In all cases, the ELISA
was inconclusive for male-treated and pre-injection hellbenders. Everything reacted with
antibodies #498, #547, #90, and #92 and did not react to anti-turtle.
The lack of a positive reaction between an obvious 200kDa protein, resembling
vitellogenin, seen in the SDS-PAGE and DEAE chromatography of these three experiments and
the hellbender experiment was evidence enough that an antibody specific for salamander
vitellogenin was necessary in order to detect the presence of this 200kDa protein in this species.
However, to first rule out the possibility of the mystery protein being albumin, a Western
blot was used to test if the 100kDa protein was possibly antigenically similar to albumin. No
commercial antibody against salamander serum albumin was found, but polyclonal antibodies
raised against chicken serum albumin was available. The antisera crossreacted with a band from
salamander sera at 66kDa. The intensity of 66kDa staining in the Western blots was greater for
the control salamander sera compared to the estrogen-treated salamander sera, indicating a
greater abundance of the 66kDa protein in control animals. All animals again reacted also with
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the 100kDa protein, and so it was established that the mystery protein was not albumin (Figure
31).
Polyclonal antibodies were produced against the conserved amino acid sequence of
vitellogenin we obtained according to standard procedures. After a BLAST search of this
sequence against various other vitellogenin amphibian species, it was decided that a little
alteration of the sequence was necessary before antibody production. Therefore, the following
sequence was the one sent to have the antibody made against: “EPVFSESKISVYNYEAVI”.
Antibodies against salamander vitellogenin were raised in rabbits using MAP technology by
Invitrogen (Carlsbad, CA). The antibodies (#371 and #358), arrived and were analyzed using
ELISA and Western blotting against a number of salamander samples (Figure 32). Reactivity
was only seen in estrogen-treated samples one time out of four tries. In conclusion, the Western
also showed no reactivity to either antibody. An ELISA using the peptide as antigen revealed no
crossreactivity against the antibodies.
After this series of inconclusive ELISAs, the antibodies against salamander vitellogenin
were remade by a new company (Sigma Genosys) using KLH technology. The antibodies (#129
and #130), arrived and were analyzed using ELISA and Western blotting against a number of
salamander samples. Western blotting showed only reactivity to either antibody against the
100kDa band seen previously (Figure not shown). Another Western was performed using
Alkaline Phosphatase methods to establish if a reaction would be seen, however, the only
reaction again was against the 100kDa band seen previously (Figure 33). Reactivity against
estrogen-treated salamander samples was only seen when running the ELISA using Alkaline
Phosphatase methods in creating a titration curve against both antibodies #129 and #130 (Figure
34, 35).
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Figure 1. Denaturing polyacrylamide gel (SDS-PAGE) of cytosol from control and estrogen-treated
Ambystoma tigrinum. Lane assignments are as follows: 1-5 = estrogen-treated; 6, 12 = molecular weight
standards (S); 7-11 = vehicle-treated; 13-15 = initial controls. See methods for treatment regimens. Cytosol was
separated on a 4 to 15% polyacrylamide gradient gel and stained with Coomassie blue.
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Figure 2: Denaturing polyacrylamide gel (SDS-PAGE) of sera from control and estrogen-treated
Ambystoma tigrinum. Lane assignments are as follows: 1 = molecular weight standards (S); 2, 4, 6, 8, 10 =
control animals (C) #1-5, respectively; 3, 5, 7, 9, 11 = estrogen-treated animals (E) #1-5, respectively. See
methods for treatment regimens. Sera were separated on a 4 to 15% polyacrylamide gradient gel and stained
with Coomassie blue.
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Figure 3: Non-denaturing polyacrylamide gel (PAGE) of sera from control and estrogen-treated
Ambystoma tigrinum. Lane assignments are as follows: 1-5 = estrogen-treated animals; 6 = molecular weight
standards (S); 7-11 = control animals.
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Figure 4: Denaturing polyacrylamide gel (SDS-PAGE) of single-injection sera from control and
estrogen-treated Ambystoma tigrinum. Lane assignments are as follows: 1-2 = male estrogen-treated (E); 3-4
= male control animals (C); 5 = molecular weight standards (S); 6-7 = female estrogen-treated(E); 8-9 = female
control animals (C); VTG = presumptive vitellogenin. See methods for treatment regimens. Sera were
separated on a 4 to 15% polyacrylamide gradient gel and stained with Coomassie blue.
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Figure 5: Denaturing polyacrylamide gel (SDS-PAGE) of multi-injection cytosol from control and
estrogen-treated Ambystoma tigrinum. Lane assignments are as follows: 1-3 = controls; 4, 8 = molecular
weight standards (S); 5-7 = high dose estrogen-treated; 9-10 = low dose estrogen-treated. See methods for
treatment regimens. Cytosol was separated on a 4 to 15% polyacrylamide gradient gel and stained with
Coomassie blue.
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Figure 6: Denaturing polyacrylamide gel (SDS-PAGE) of multi-injection sera from control and estrogentreated Ambystoma tigrinum. Lane assignments are as follows: 1-3 = controls; 4, 8 = molecular weight
standards (S); 5-7 = high dose estrogen-treated; 9-10 = low dose estrogen-treated; VTG = presumptive
vitellogenin. See methods for treatment regimens. Sera were separated on a 4 to 15% polyacrylamide gradient
gel and stained with Coomassie blue.
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Figure 7: DEAE profile for sera from control and estrogen-treated Ambystoma tigrinum. Serum proteins
were separated on a DEAE-agarose column using a Bio-Rad Econo Chromatography System. Proteins were
subsequently measured by the Coomassie method for each fraction.
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Figure 8: Denaturing polyacrylamide gel (SDS-PAGE) of DEAE fractions from control and estrogentreated Ambystoma tigrinum. Lane assignments are as follows: 1-13 (odd lanes) = fractions from control
animal sera (C); 2-14 (even lanes) = fractions from estrogen-treated animal sera (E); 15 = molecular weight
standards (S). See methods for treatment regimens. Bottom numbers refer to fraction numbers from the DEAE
separation. Fractions were separated on a 4 to 15% gradient gel and stained with Coomassie blue.
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Figure 9: DEAE profile for sera from control and estrogen-treated Ambystoma tigrinum. Serum proteins
were separated on a DEAE-agarose column using a Bio-Rad Econo Chromatography System. Proteins were
subsequently measured by the Coomassie method for each fraction.
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Figure 10: Denaturing polyacrylamide gel (SDS-PAGE) of DEAE fractions from control and estrogentreated Ambystoma tigrinum. Fractions were separated on a 4 to 15% polyacrylamide gradient gel and stained
with Coomassie blue. Lane assignments are as follows: 1-9 (odd lanes) = fractions from control animal sera; 210 (even lanes) = fractions from estrogen-treated animal sera; 11 = molecular weight standards (S). See
methods for treatment regimens. Abbreviations are C = control; E = estrogen treated. Bottom numbers refer to
fraction numbers from the DEAE separation.
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Figure 11: Denaturing polyacrylamide gel (SDS-PAGE) of cytosol from control and estrogen-treated
Ambystoma tigrinum. Lane assignments are as follows: 1-3 = control; 4 = molecular weight standards (S); 511 = estrogen treated. See methods for treatment regimens. Cytosol was separated on a 4 to 15% gradient gel
and stained with Coomassie blue.
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Figure 12: Denaturing polyacrylamide gel (SDS-PAGE) of sera from control and estrogen-treated
Ambystoma tigrinum. Lane assignments are as follows: 1-3 = vehicle; 4 = molecular weight standards (S); 516 = estrogen-treated; VTG = Size of presumptive vitellogenin. See methods for treatment regimens. Sera
were separated on a 4 to 15% gradient gel and stained with Coomassie blue.
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Figure 13: Non-denaturing polyacrylamide gel (PAGE) of sera from control and estrogen-treated
Ambystoma tigrinum. Lane assignments are as follows: 1-2 = multi-injection control-treated animals (C); 3 =
multi-injection low dose estrogen treated (L); 4-5 = multi-injection high dose estrogen treated (H); 6, 9 =
molecular weight standards (S); 7 = multi-injection juvenile vehicle (V); 8 = multi-injection juvenile estrogentreated (E); 10 = single-injection male control animals (V); 11 = single-injection male estrogen animals (E); 12
= single-injection female control animals (V); 13 = single-injection female estrogen-treated (E).
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Figure 14: Denaturing polyacrylamide gel (SDS-PAGE) of sera from control and estrogen-treated
Ambystoma maculatum. Lane assignments are as follows: 1-9 = estrogen-treated; 10 = molecular weight
standards (S); 11-12 = vehicles; VTG = Size of presumptive vitellogenin. See methods for treatment regimens.
Sera were separated on a 4 to 15% gradient gel and stained with Coomassie blue.
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Figure 15: Denaturing polyacrylamide gel (SDS-PAGE) of sera from high and low atrazine-treated
Ambystoma maculatum. Lane assignments are as follows: 1-3 = vehicles from same experiment; 4-9 = atrazine
low dose; 10 = molecular weight standards (S); 11-12 = atrazine high dose. See methods for treatment
regimens. Sera were separated on a 4 to 15% gradient gel and stained with Coomassie blue.
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Figure 16: Denaturing polyacrylamide gel (SDS-PAGE) of sera from high and low aroclor-treated
Ambystoma maculatum. Lane assignments are as follows: 1-3 = vehicles from same experiment; 4-9 = aroclor
low dose; 10 = molecular weight standards (S); 11-16 = aroclor high dose. See methods for treatment regimens.
Sera were separated on a 4 to 15% gradient gel and stained with Coomassie blue.
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β-estradiolFigure 17: Denaturing polyacrylamide gel (SDS-PAGE) of sera from pre-treated and 17β
treated male Cryptobranchus alleganiensis. Lane assignments are as follows: 1-2 = animal #1, pre-treatment
(P); 3,4 = animal #1, 1st bleed; (1) 5,6 animal #1, 2nd bleed (2); 7 = molecular weight standards (S); 8, 9 =
animal #2, pre-treatment (P); 10, 11 = animal #2, 1st bleed (1); 12, 13 animal #2, 2nd bleed (2); VTG =
Presumptive vitellogenin. See methods for treatment regimen. Sera were separated on a 4 to 15% gradient gel
and stained with Coomassie blue.
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Figure 18: DEAE profile for sera from control and estrogen-treated Cryptobranchus alleganiensis.
Serum proteins were separated on a DEAE-agarose column using a Bio-Rad Econo Chromatography System.
Proteins were subsequently measured by the Coomassie method for each fraction.
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Figure 19: Denaturing polyacrylamide gel (SDS-PAGE) of DEAE fractions from control (C) and
estrogen-treated (E) Cryptobranchus alleganiensis. Fractions were separated on a 4 to 15% gradient gel and
stained with Coomassie blue. Lane assignments are as follows: 1 = Male serum (M); 2 = Female serum (F); 3 =
molecular weight standards (S); 4-14 (even lanes) = control treated animals; 5-15 (odd lanes) = estrogen-treated
animals. Abbreviations are C=control; E=estrogen treated; VTG = Presumptive vitellogenin. Numbers refer to
fraction numbers from the DEAE separation.
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Figure 20: Denaturing polyacrylamide gel (SDS-PAGE) of sera from male and female Crocodylus
moreletii. Lane assignments are as follows: 1-6 = male wild caught animals; 7 = molecular weight standards
(S); 8-13 = female wild caught animals; VTG = Presumptive vitellogenin. See methods for treatment regimens.
Sera were separated on a 4 to 15% gradient gel and stained with Coomassie blue.
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Figure 21: Denaturing polyacrylamide gel (SDS-PAGE) (top panel) and Western blot (bottom panel) of
sera from male and female Crocodylus moreletii. Lane assignments are as follows: 1-6 = female wild caught
animals; 7 = molecular weight standards (S); 8-13 = male wild caught animals; VTG = Presumptive
vitellogenin. See methods for treatment regimens. Sera were separated on a 4 to 15% gradient gel and stained
with Coomassie blue. For Western blotting, the primary antiserum (polyclonal antiserum #498) was used at a
1:100 dilution and the second antibody was used at a 1:1000 dilution.
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Figure 22: Vitellogenin enzyme linked immunosorbent assay (ELISA) of pooled male (blue circles) and
female (pink circles) Crocodylus moreletii sera. See methods for treatment regimens. Samples were diluted
1:1000 and the primary antiserum (polyclonal #498) was serially diluted from 1:1000 to 1:128,000, as indicated.
The secondary antibody was used at a 1:1000 dilution.
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Figure 23: Vitellogenin enzyme linked immunosorbent assay (ELISA) of pooled male and female
Crocodylus moreletii sera. See methods for treatment regimens. Bars represent the mean of eight samples.
Samples were diluted 1:1000 and the primary antiserum (polyclonal #498) was diluted 1:1000. The secondary
antibody was used at a 1:1000 dilution.
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Figure 24: DEAE profile for sera from male and female Crocodylus moreletii. Serum proteins were
separated on a DEAE-agarose column using a Bio-Rad Econo Chromatography System. Proteins were
subsequently measured by the Coomassie method for each fraction.
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Figure 25: Denaturing polyacrylamide gel (SDS-PAGE) of DEAE fractions from male and female
Crocodylus moreletii. Lane assignments are as follows: 1 = Male serum; 2 = Female serum; 3-13 (odd lanes) =
estrogen-treated animals (E); 4-14 (even lanes) = control treated animals (C); 15 = molecular weight standards
(S). Abbreviations are M=male; F=female treated; VTG = Presumptive vitellogenin. Numbers refer to fraction
numbers from the DEAE separation. Fractions were separated on a 4 to 15% gradient gel and stained with
Coomassie blue.
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Figure 26: Denaturing polyacrylamide gel (SDS-PAGE) (left) and Western blot (right) of sera from
estrogen-treated and wild caught Rana aurora. Lane assignments are as follows: 1-5 = estrogen-treated
animals; 6 = molecular weight standards (S); 7-9 = wild caught animals; VTG = Presumptive vitellogenin. See
methods for treatment regimens. Sera were separated on a 4 to 15% gradient gel and stained with Coomassie
blue. For Western blotting, the primary antiserum (polyclonal antiserum #498) was used at a 1:100 dilution and
the second antibody was used at a 1:1000 dilution.
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Figure 27: Denaturing polyacrylamide gel (SDS-PAGE) (top panel) and Western blot (bottom panel) of
sera from control and estrogen-treated Ambystoma tigrinum. Lane assignments are as follows: 1-5 =
estrogen-treated animals; 6, 12 = molecular weight standards (S); 7-11 = vehicle treated animals; 13-14 = initial
controls. See methods for treatment regimens. Sera were separated on a 4 to 15% gradient gel and stained with
Coomassie blue. For Western blotting, the primary antiserum (polyclonal antiserum #498) was used at a 1:100
dilution and the second antibody was used at a 1:1000 dilution.
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Figure 28: Denaturing polyacrylamide gel (SDS-PAGE) (bottom panel) and Western Blot (top panel) of
DEAE fractions from male and female Ambystoma tigrinum. Lane assignments are as follows: 1-13 (odd
lanes) = control treated animals (C); 2-14 (even lanes) = estrogen-treated animals (E); 15 = molecular weight
standards (S). Abbreviations are VTG = Presumptive vitellogenin. Numbers refer to fraction numbers from the
DEAE separation. Fractions were separated on a 4 to 15% gradient gel and stained with Coomassie blue. For
Western blotting, the primary antiserum (polyclonal antiserum #498) was used at a 1:100 dilution and the
second antibody was used at a 1:1000 dilution.
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Figure 29: Denaturing polyacrylamide gel (SDS-PAGE) (not shown) and Western blots of sera from
control and estrogen-treated Ambystoma tigrinum. Lane assignments are as follows: 1, 4, 7, 10, 13 =
estrogen-treated animals (E); 2, 5, 8, 11, 14 = control animals (C); 3, 6, 9, 12, 15 = molecular weight standards
(S). See methods for treatment regimens. Sera were separated on a 4 to 15% gradient gel. For Western
blotting, the primary antiserum (noted above the lanes) were used at a 1:1000 dilution and the second antibody
was used at a 1:1000 dilution.
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Figure 30: Denaturing polyacrylamide gel (SDS-PAGE) (not shown) and Western blots of sera from
control and estrogen-treated Cryptobranchus alleganiensis. Lane assignments are as follows: 1, 4, 7, 10, 13
= pre-treated animals (P); 2, 5, 8, 11, 14 = estrogen-treated animals (2); 3, 6, 9, 12, 15 = molecular weight
standards (S). See methods for treatment regimens. Sera were separated on a 4 to 15% gradient gel. For
Western blotting, the primary antiserum (noted above the lanes) were used at a 1:1000 dilution and the second
antibody was used at a 1:1000 dilution.
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Figure 31: Denaturing polyacrylamide gel (SDS-PAGE) (not shown) and Western blots of sera from
control, estrogen-treated Ambystoma tigrinum, and Cryptobranchus alleganiensis. Lane assignments are as
follows: 1 = molecular weight standards (S); 2 estrogen-treated Cryptobranchus alleganiensis (E); 3 = pretreatment Cryptobranchus alleganiensis (P); 4, 6 = estrogen-treated Ambystoma tigrinum (E); 5, 7 = vehicle
treated Ambystoma tigrinum (C). See methods for treatment regimens. Sera were separated on a 4 to 15%
gradient gel. For Western blotting, the primary antiserum (rabbit-anti-chicken-anti-albumin) was used at a
1:1000 dilution and the second antibody was used at a 1:1000 dilution.

81

1 2 3 4 5 6 7 8 9 10 11 12 13 14
E V A P S S E V A P
371
358
Figure 32: Denaturing polyacrylamide gel (SDS-PAGE) (not shown) and Western blots of sera from
control, estrogen- and xenobiotic-treated Ambystoma tigrinum. Lane assignments are as follows: 1-2, 9-10
= estrogen-treated animals (E); 3-4, 11-12 = vehicle treated animals (V); 5,13 = atrazine-treated animals (A); 6,
14 = aroclor-treated animals (P); 7-8 = molecular weight standards (S). See methods for treatment regimens.
Sera were separated on a 4 to 15% gradient gel. For Western blotting, the primary antiserum (left side of gel is
#371; right side of the gel was #358) was used at a 1:1000 dilution and the second antibody was used at a
1:1000 dilution.
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Figure 33: Denaturing polyacrylamide gel (SDS-PAGE) (not shown) and Western blots of sera from
control, estrogen-treated Ambystoma tigrinum, and Cryptobranchus alleganiensis. Lane assignments are as
follows: 1, 3, 9, 11 = vehicle treated Ambystoma tigrinum (C); 2, 4, 10, 12 = estrogen-treated Ambystoma
tigrinum (E); 5, 12 = pre-treatment Cryptobranchus alleganiensis (P); 6, 13 estrogen-treated Cryptobranchus
alleganiensis (E); 7, 14 = atrazine-treated animals (A); 6, 14 = aroclor-treated animals (P); 7-8 = molecular
weight standards (S). See methods for treatment regimens. Sera were separated on a 4 to 15% gradient gel. For
Western blotting, the primary antiserum (left side of gel is #130; right side of the gel was #129) was used at a
1:1000 dilution and the second antibody was used at a 1:1000 dilution.
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Figure 34: Vitellogenin enzyme linked immunosorbent assay (ELISA) of estrogen-treated (black circles)
and control (white circles) Ambystoma tigrinum juvenile sera. See methods for treatment regimens.
Samples were diluted 1:3000 and the primary antiserum (#129) was serially diluted from 1:500 to 1:16,000, as
indicated. The secondary antibody was used at a 1:1000 dilution.
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Figure 35: Vitellogenin enzyme linked immunosorbent assay (ELISA) of estrogen-treated (black circles)
and control (white circles) Ambystoma tigrinum juvenile sera. See methods for treatment regimens.
Samples were diluted 1:3000 and the primary antiserum (#130) was serially diluted from 1:500 to 1:16,000, as
indicated. The secondary antibody was used at a 1:1000 dilution.
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Discussion
A substantial number of chemicals in the environment possess estrogenic activity (McLachlan,
1993). These chemicals include a wide range of natural and manufactured compounds, such as plant and
fungal products, plasticizers, industrial chemicals, and pesticides (Danzo, 1998). Most of these chemicals
eventually enter the water, making aquatic organisms more susceptible to their effects. Many wildlife
species, in particular amphibians, are experiencing population declines. Endocrine disruption is suspected
to play a role in this, although there is insufficient data to prove this assumption (Carey and Bryant,
1995). Amphibians are ideal biological indicators, because their semi-permeable epidermis and complex
life cycle expose them to multiple stressors in both aquatic and terrestrial environments (Wyman, 1990).
A reliable method of detecting and classifying xenobiotic estrogens in wildlife species is needed due to
the major concern that these estrogenic chemicals persisting in the environment may be adversely
affecting the health of wildlife and humans (Blaustein and Wake, 1990; Raloff, 1994; Wake, 1991; Carey
and Bryant, 1995; Colborn et al., 1993). Vitellogenin induction has shown promise as a sensitive and
useful biomarker of wildlife exposure to xenobiotic estrogens, predominantly in aquatic systems (Palmer
and Palmer, 1995; Sumpter and Jobling, 1995; Folmar et al., 1996; Purdom et al., 1994). There have been
no previous studies using salamanders as a model species to test for the presence of endocrine disruption,
or to assess estrogenicity using vitellogenin as a biomarker. Therefore, in the present study, vitellogenin
was used as a biomarker for environmental estrogens in the amphibian model Ambystoma tigrinum.
The first objective of this research was to characterize the changes in serum proteins associated
with estrogen exposure. The second objective was to develop immunoassays for detecting changes in
vitellogenin and perhaps other proteins for the future use in studies of endocrine disruption. The third
objective was to employ these assays to evaluate responses to specific endocrine-disrupting chemicals.
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The specific type of Ambystoma tigrinum that we wished to use in this study were adult male tiger
salamanders. We chose males because we wanted to evaluate the effects of being exposed to estrogen
without having an endogenous supply, as would be the case in females. We did use females, though, to
obtain positive controls. However, adult tiger salamanders were not always available, so when they were
unavailable, we used juveniles, which also lack endogenous estrogens. The only problem with using
juveniles was that we were unable to determine their gender. Another problem was availability of the
salamander species of choice. We intended to use Ambystoma tigrinum consistently throughout all
studies. However, there were long periods of time where Ambystoma tigrinum was unavailable, so in
order to proceed, we were forced to use Ambystoma maculatum, the spotted salamander.
The method of delivering the estrogen was also changed during the project. We first dissolved the
steroid into corn oil. However, after the first experiment was unsuccessful and doing further literature
searches, it seemed that the most current method of delivering the estrogen was by dissolving it into
propylene glycol. The type of estrogen also varied. We began to use the natural salamander estrogen,
17ß-estradiol. However again, after the first experiment was unsuccessful and doing further literature
searches it was noted that most studies were using ethinyl-estradiol, the active ingredient in birth control
pills. We realized that this was the most relevant option, since women using birth control pills in
increasing numbers places an increased amount of estrogen and their breakdown products through sewage
treatment plants and into the waterways. This exposes wildlife because these waters serve as nurseries for
offspring and breeding ponds for mature animals. Therefore, we switched to using ethinyl-estradiol for
the further studies.
Although our studies of vitellogenin induction in salamanders were begun by injection, there have
been no studies for vitellogenin induction by immersion in salamanders. While injection and oral dosing
are common used methods for delivery of experimental compounds for studies of toxicity, immersion is a
more appropriate for testing the effects of waterborne contaminants. Although I did wish to evaluate
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vitellogenin induction in salamanders via immersion, the unavailability of aquatic salamanders prohibited
this type of exposure.
Salamander Experiments
While previous work in our lab used DES as the stimulant for vitellogenin induction, we chose to
first use 17ß-estradiol instead. Interestingly, there was no evident induction of vitellogenin in the male
salamanders after four weeks. SDS-PAGE analysis of sera and cytosol Ambystoma tigrinum samples
revealed no presence of vitellogenin. This was perplexing because most studies have shown vitellogenin
induction after estrogen injections. One explanation is that the salamanders that we received were
neotenic salamanders. The supplier advised us to keep them in the cold, 3° C, in order to keep them alive.
While they lived well for a month, their metabolism was certainly slowed down, and they would not eat.
They may not have reacted to estrogen treatments because they could not respond to the injections or
because the estrogen could not come out of the oil at that temperature. It has been shown in turtles and
fish that steroid receptors do not bind hormones in the cold as efficiently as they do in warmer
temperatures (Licht et al., 1990; Tsai et al., 2003). There is a blockage of the potassium channels, which
does not allow for proper hormone-receptor binding (Licht et al., 1990). A very recent study also found
that an exposure at a lower temperature than room temperature (20° C) resulted in a significant decrease
in the expression of estrogen receptor alpha while estrogen receptor beta was unaffected by temperature
(Tsai et al., 2003).
Discontentedly to many women beginning birth control, estrogen has been noted to induce weight
gain, as an example, DES was administered to livestock in order for them to gain weight (Palmer and
Selcer, 1996). On the contrary, endocrine disruptors have been shown to have the opposite effect; they
have been shown to induce weight loss in exposed animals, as in the case of atrazine exposure to tiger
salamanders (Larson et al., 1998). Salamanders in the current study were expected to have a difference in
body weight from the controls when exposed to estrogen treatments. In the first experiment, estrogen did
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significantly decrease the body weight of salamanders while at the same time significantly increasing their
total serum protein concentration. However, further salamander experiments did not demonstrate this
same decrease in body weight and were inconclusive as to whether estrogen treatment had a significant
effect on body weight. Further experiments are necessary to determine if there is a linkage between
estrogen exposure and a reduction in body weight.
For the next experiment, the estrogen was changed to ethinyl-estradiol, a component of the female
birth control pill. The salamanders that we used were fully transformed adult male, female, and juvenile
tiger salamanders. Being fully transformed, they were not kept in the cold, but were incabuted at room
temperature. These experiments did indeed show that vitellogenin was inducible in both male and female
salamanders when exposed to estrogen, and revealed that both adults and juveniles could serve as
appropriate models for further experiments on vitellogenin induction by environmental estrogens. SDSPAGE clearly showed a band in the 200kDa range in the female and estrogen-treated samples. This
protein was never present in the control samples. This is consistent with known vitellogenin from
amphibian and reptile species, weighing approximately 200kDa, while fish vitellogenins weigh less,
approximately 160kDa (Selcer et al., 2001).
DEAE chromatography was performed on Ambystoma tigrinum estrogen-treated and control male
samples to determine if the estrogen-induced vitellogenin protein has the same characteristics as it does in
other species. DEAE revealed the consistent presence of this 200kDa protein in the estrogen-treated
samples but not in the control samples. The DEAE profile that was created from the estrogen-treated and
control male Ambystoma tigrinum were very similar to those created from the red-eared slider turtle,
Trachemys scripta, (Selcer and Palmer, 1995) and also the African Clawed Frog, Xenopus laevis (Palmer
and Palmer, 1995). In all three species, there was a very distinct peak that eluted at high salt, which is
representative of vitellogenin, in the estrogen-treated samples that was clearly absent in the control or
male samples. This difference was also evident in densitometry readings of the SDS-PAGE fractions.
Vitellogenin in vertebrates is known to bind to DEAE and only elute at high salt. When fractions from
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the DEAE-agarose high salt peak were run on SDS-PAGE, only the 200kDa band was seen in the
estrogen-treated samples and no bands were present in the control samples, the same as in Trachemys
scripta. This demonstrates further that not only is this protein in the treated-male Ambystoma tigrinum
samples vitellogenin (due to it eluting at high salt), but it also consistently behaves like the protein
vitellogenin in many other different species. An ulterior motive in purifying the salamander vitellogenin
by DEAE was to prepare it for sequencing to further assure that this protein was vitellogenin. The Nterminal sequencing determined that this protein is closely related to other vertebrate vitellogenins,
especially the African clawed frog, Xenopus laevis, (Germond, et al., 1984) and the hellbender,
Cryptobranchus alleganiensis.
In order to test if xenobiotics had an effect on vitellogenin induction, we chose to first use aroclor
1221 (a mixture of PCBs) and atrazine as the representatives of environmental estrogens. Interestingly,
there was no evident induction of vitellogenin in the juvenile salamanders. SDS-PAGE analysis of serum
Ambystoma maculatum samples revealed no presence of vitellogenin in treated individuals. One
possibility for the lack of response is that the dose was insufficient, (i.e., it was not high enough to bring
them over the threshold necessary to produce vitellogenin). Some studies have reported that aroclor does
not induce vitellogenin when administered alone; however, it does produce a vitellogenin response when
added with other xenobiotics such as DDT, Bisphenyl A, and nonylphenol (Arukwe et al., 2000).
Another recent study found that 4'-MeSO (2)-PCBs are antiestrogenic in vitro and while MeSO (2)-PCB
metabolites are persistent and bioaccumulative contaminants, they could be potentially active as
environmental antiestrogens in wildlife and humans (Letcher et al., 2002). Another study of atrazine and
male carp hepatocytes displayed that none of the triazine herbicides nor their metabolites induced
vitellogenin production in male carp hepatocytes, indicating that the estrogenic effects associated with the
triazine herbicides in vivo are not estrogen receptor-mediated, but may be explained partly by their ability
to induce aromatase in vitro (Sanderson et al., 2001). Behavioral or developmental effects may prove to
be better biomarkers for these compounds than vitellogenin induction. A study looking at the behavioral
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effects of atrazine on tiger salamanders using relevant concentrations to ours found that when exposed to
atrazine, plasma thyroxine was elevated, plasma corticosterone was depressed, larvae reached
developmental stage 4 later, at a smaller size, and lower weight. These results indicate that the herbicide
atrazine has the potential to influence tiger salamander life history (Larson et al., 1998). A study done
with Xenopus and aroclor 1254 showed that exposure caused alterations in gross morphology and
swimming behavior and statistically significant decreases in survival and gene expression (Jelaso et al.,
2002).
Polyclonal Antibody Production
The utilization of vitellogenin as a biomarker in immunoassays is based on the ability of an
antibody to recognize this protein. Several broadly cross-reactive vitellogenin antibodies have been
previously developed (Denslow et al., 1996; Heppel et al., 1995). In our lab, a polyclonal broadlycrossreactive antibody for vitellogenins was developed by Phil Foret, 1998 (Selcer et al., 2001). This
antibody cross-reacts in immunoassays with representative species of fish, amphibian, and reptile classes.
However, this antibody, #498, and a few others, #547, Rana-specific (#90, #92), and anti-turtle, did not
react against salamander vitellogenin. The puzzling part is that we know that the vitellogenin is present,
as we demonstrated previously. In a number of Western blots and ELISAs against salamanders from each
experimental design, none reacted against vitellogenin using any of these antibodies.
A further problem was most antibodies we tried reacted with another protein non-specifically in
both the control and estrogen-treated salamander samples. This band was always present in the Western
blots, and using either detection system (DAB or Alkaline Phosphatase). The only time that the band was
not present was when using anti-turtle antibody, and this we feel is because that antibody was affinity
purified, so as to alleviate this non-specific binding. We know that this unidentified protein is not
albumin, as when we did a Western blot against anti-chicken albumin, the unidentified protein reacted at a
weight of approximately 100kDa along with a reaction of albumin at the weight of 66kDa. Since this
91

unidentified protein was binding so strongly, it was also masking the potential antibody-vitellogenin
reactivity in ELISAs. Since this was the case, we decided to manufacture a salamander-specific antibody.
There were two strategies that we considered when making the antibody (Palmer and Selcer,
1996). The first was to purify the protein, and then send it off for production of an antibody. The second
was to sequence the protein, and then use the sequence to make a peptide, and then create an antibody
against that peptide. Since we had received the salamander vitellogenin N-terminal sequence already, we
decided to do the latter (i.e., have a peptide synthesized and raise antibodies to that peptide). The
antibody that we received from Invitrogen using the MAP standard technologies was not a salamanderspecific antibody. Being over 3 months late, the antibody they sent did not recognize the peptide it was
generated against when tested with an ELISA. From these results, we chose to re-produce the antibody.
The second time the antibody was constructed, we used the same sequence, but ordered from Sigma
Genosys, and used the KLH-coupling approach. This time the antibody at least recognized the peptide
when screening with ELISA. The results we have obtained so far are still inconclusive. There have been
times that it appeared to work, and times that it did not. We cannot conclude if this is because of the
unidentified protein causing interference, or if there is still an issue with dilutions, or that the salamander
samples are starting to break-down, since we have had them for so long. Further studies need to be
conducted in order to establish the utility of the salamander-specific antibody.
Hellbender Experiment (Cryptobranchus alleganiensis)
Pre-treated and estrogen-treated male Cryptobranchus alleganiensis serum samples were sent to
us to be screened for vitellogenin. SDS-PAGE was used to identify estrogen-induced proteins. SDSPAGE clearly showed a band in the 200kDa range in the estrogen-treated samples. This protein was not
present in the pre-treatment samples. Estrogen-treated Alligator mississippiensis samples ran on SDSPAGE also showed a band at approximately 220kDa in the estrogen-treated samples but were not present
in the untreated plasma (Selcer et al., 2001).
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DEAE chromatography was performed on Cryptobranchus alleganiensis pre-treatment and
estrogen-treated male samples to determine if the estrogen-induced vitellogenin protein behaves the same
way as it does in previously characterized species. The DEAE revealed the consistent presence of a
200kDa protein in the estrogen-treated samples but not in the pre-treatment samples. The DEAE profile
that was created from the pre-treatment and estrogen-treated Cryptobranchus alleganiensis were very
similar to those created from the red-eared slider turtle, Trachemys scripta, (Selcer and Palmer, 1995)
Xenopus laevis (Palmer and Palmer, 1995) and for Ambystoma tigrinum. In all three species, there was a
very distinct peak that eluted at high salt, which is representative of vitellogenin, in the estrogen-treated or
female samples that was clearly absent in the control or male samples. This demonstrates further that not
only is this protein in the estrogen-treated Cryptobranchus alleganiensis samples vitellogenin, but that it
also consistently behaves like the protein vitellogenin in many other different species. An ulterior motive
in purifying the hellbender vitellogenin was to prepare it for sequencing to further assure that this protein
was vitellogenin. The sequencing determined that this protein is closely related to other vertebrate
vitellogenins, especially the African clawed frog, Xenopus laevis, (Germond, et al., 1984), and the
salamander, Ambystoma tigrinum.
The plasma samples were first tested against polyclonal antiserum #498. This antibody has been
shown to be effective at detecting vitellogenin in a number of species, including Xenopus laevis,
Carassius auratus, Sphyrna tiburo, Trachemys scripta, and Alligator mississippiensis (Selcer et al., 2001).
This diversity of animals show that the antibody displays broad cross-reactivity against representatives of
four vertebrate classes, Chondrichthyes, Osteichthyes, Amphibia, and Reptilia (Selcer et al., 2001). We
felt that it would also show reactivity against Cryptobranchus alleganiensis vitellogenin.
Reactivity of the presumptive vitellogenin with the antiserum #498 was tested by Western blotting
with vitellogenic and nonvitellogenic samples. Western blotting showed that antiserum #498 showed no
cross-reactivity with the presumptive vitellogenin protein in any samples. The only band that could be
seen was the same unidentified protein found for Ambystoma tigrinum in both the pre-treatment and
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estrogen-treated samples. The results of the Western blotting are consistent with that of control and
estrogen-treated Ambystoma tigrinum samples. Even when doing an antibody screen of antibodies, #498,
#547, #90, #92, and anti-turtle, there was no reactivity in any lanes except the unidentified protein present
in all lanes (estrogen-treated and pre-treatment) except against anti-turtle. Again, the only time that the
band was not present was when using anti-turtle antibody, and this we feel is because that antibody was
affinity purified, so as to alleviate this non-specific binding. The newly produced salamander antibody
also does not appear to react with either the pre-treated or estrogen-treated Cryptobranchus alleganiensis
samples at this time.
Reactivity of the presumptive vitellogenin with the antiserum was also tested by ELISA to
determine the reactivity of the antiserum #498 with vitellogenic and nonvitellogenic samples. The ELISA
also demonstrated that this broadly cross-reactive antiserum had no cross-reactivity with the pre-treatment
or estrogen-treated males. Again, these results are consistent with other salamander species, control and
estrogen-treated Ambystoma tigrinum samples. The newly produced salamander antibody still does not
appear to react with either the pre-treated or estrogen-treated Cryptobranchus alleganiensis samples at
this time.
Crocodile Experiment (Crocodylus moreletii)
Three-hundred and eighty-one male and female Crocodylus moreletii wild-caught samples from
potentially contaminated lakes in Belize were sent to us to be screened for vitellogenin. The plasma
samples were tested against polyclonal antiserum #498. This antibody has been shown to be effective at
detecting vitellogenin in a number of species, Xenopus laevis, Carassius auratus, Sphyrna tiburo,
Trachemys scripta, and Alligator mississippiensis. This diversity of animals show that the antibody
displays broadly cross-reactivity against representatives of four vertebrate classes, Chondrichthyes,
Osteichthyes, Amphibia, and Reptilia (Selcer et al., 2001). Especially since it showed reactivity with
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Alligator mississippiensis, we felt that it would also show reactivity against Crocodylus moreletii
vitellogenin.
SDS-PAGE was used to identify female-specific or estrogen-induced proteins. SDS-PAGE
clearly showed a band in the 210kDa range in the female samples. This protein was not present in the
male samples. Estrogen-treated Alligator mississippiensis samples ran on SDS-PAGE also showed a
band at approximately 220kDa in the estrogen-treated samples that were not present in the untreated
plasma (Selcer et al., 2001).
Reactivity of the presumptive vitellogenin with the antiserum was tested by Western blotting to
determine the reactivity of the antiserum #498 with vitellogenic and nonvitellogenic samples. Western
blotting showed that antiserum #498 strongly cross-reacted with this protein only in the female samples,
and showed no reactivity at all with male samples. Multiple bands were seen in the female samples
(approximately three), where none were seen in the male samples. The strongest reactivity occurred
against the presumptive vitellogenin (approximately 210kDa). The other two bands that showed weak
reactivity in the female serum occurred directly above and below where albumin would have been
(approximately 66kDa). Since these bands were not present in the control sera, they may represent
degradation products of vitellogenin. The results of the Western blotting are again consistent with that of
estrogen-treated Alligator mississippiensis samples. Western blotting of Alligator mississippiensis
samples against antiserum #498 showed strong cross-reactivity with the 220kDa band only in the
estrogen-treated samples, and also some weak cross-reactivity with a few other bands again around the
albumin range (66kDa) (Selcer et al., 2001). Again, these proteins were only present in estrogen-treated
serum, and were absent in the controls, suggesting that these proteins may be breakdown proteins of
vitellogenin.
Reactivity of the presumptive vitellogenin with the antiserum was also tested by ELISA using
vitellogenic and nonvitellogenic samples. The ELISA also demonstrated that this broadly cross-reactive
antiserum had much greater reactivity with the females and none with the male sera. These experiments
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established the effectiveness of broadly crossreactive antiserum #498 for detection of Crocodylus
moreletii vitellogenin. The titration curve that was established for Crocodylus moreletii looked very
similar to that of Alligator mississippiensis described previously, again showing that antibody #498
showed reactivity to a female specific protein vitellogenin in multiple species (Selcer et al., 2001).
DEAE chromatography was performed on Crocodylus moreletii female and male samples to
determine if the female vitellogenin protein behaves the same way as it does in previously characterized
species. The DEAE revealed the consistent presence of this 210kDa protein in the female samples but not
in the male samples. The DEAE profile that was created from the female and male Crocodylus moreletii
were very similar to those created from the red-eared slider turtle, Trachemys scripta, (Selcer and Palmer,
1995), for Xenopus laevis (Palmer and Palmer, 1995) and for Ambystoma tigrinum. In all three species,
there was a very distinct peak that eluted at high salt, which is representative of vitellogenin, in the
estrogen-treated or female samples that was clearly absent in the control or male samples. This
demonstrates further that not only is this protein in the female Crocodylus moreletii samples vitellogenin,
but that it also consistently behaves like the protein vitellogenin in many other different species. These
series of experiments also demonstrated that endocrine disruption did not seem to be occurring in the that
wild caught animals from this lake despite the fact that the animals were known to have been exposed to
pollutants.
Rana aurora Experiment
One-hundred and fifty-five Rana aurora wild-caught samples were sent to us from California to
be screened for vitellogenin. Before screening all samples, an initial screening was conducted to ensure
the proper working conditions of the assay. SDS-PAGE, Western blotting, and ELISAs were conducted
using Rana aurora females as a positive control and wild-caught samples. The SDS-PAGE showed all
samples to show the presence of the protein, presumably vitellogenin (180kDa). The Western blot using
vitellogenin-antiserum #92 (a Rana-specific antibody) only showed cross-reactivity in three of five
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estrogen-treated female samples, and showed no reactivity with any of the wild-caught samples. This
lack of reactivity with the other two estrogen-treated female samples may have occurred due to the fact
that the female samples were very old samples, and had gone through many potential degradation periods
due to faulty handling. The ELISA using the five Rana aurora wild-caught males, along with positive
and negative Rana aurora controls in the antibody screen only showed reactivity in the positive control
serum against the Rana specific antibodies, antibody #90, and more strongly against antibody #92.
Antibody #92 was thus selected to be used as the anti-vitellogenin for screening all of the wild-caught
Rana aurora samples for their presence of vitellogenin.
In the ELISA assays, some females showed a positive response for vitellogenin. Although 2 of
the juveniles and 2 of the non-distinguishables did show positive for vitellogenin production, it is unclear
whether they were female samples and were not able to be sexed properly. From this study, it can be
concluded that only 8.39% of the population of the lake were vitellogenic, meaning that only a subset of
the females were reproductive at the time, while no males showed positive for vitellogenin at any time. It
can be speculated that the lake is not being exposed to xenobiotic estrogenic agents, since there was no
presence of vitellogenin in any samples except females.
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Conclusions and Future Directions

It is likely that there will be concern regarding the potential risks of chemical contaminants and
possibilities of exposure to the public well into the future. Many wildlife species, in particular
amphibians, are experiencing population declines. While many feel that there is no link between human
or wildlife health and estrogenic chemicals, few studies have been conducted to investigate these issues.
There are insufficient data to prove either assumption.
The salamander vitellogenin experiments have provided valuable background information on
vitellogenin induction. The salamander vitellogenin assay developed will be useful in screening for
environmental estrogens. After in vitro screening, this in vivo assay will give more information about the
effects of certain chemicals on the entire animal. This assay can also be used to study the effects of antiestrogenic compounds.
Future directions include performing many more experiments to evaluate the suspected effects of
environmental estrogens on salamanders. If more salamander samples are accessible, it would be wise to
continue analyzing the antibody to determine the appropriate dilutions necessary to ensure that the assay
is working at its optimal capabilities. Perhaps if this antibody does not work at levels that are felt to be
optimal, there will be a necessity to produce a new antibody from the purified protein, which would allow
for a stronger crossreactivity between the vitellogenin and the primary antibody. Another experiment to
pursue after concluding that the assay was working at optimal conditions would be to evaluate the antiestrogenic effects on amphibians, particularly salamanders, of endocrine disrupting chemicals such as
aroclor 1221 and atrazine. This would be an extremely valuable technique for measuring the impact of
these compounds on female reproduction and for assessing the detriment to their offspring.
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Appendix 1 – Listing of all Potential Anti-Vitellogenin Antibodies Used in this Study

Antibody
#498
#547
#90
#92
Anti-Turtle
#371
#358
#129
#130

Description
Broadly-cross reactive polyclonal antibody generated against a
conserved vitellogenin peptide
Broadly-cross reactive polyclonal antibody generated against a
conserved vitellogenin peptide
Antibody generated against a purified Rana pipiens
vitellogenin protein
Antibody generated against a purified Rana pipiens
vitellogenin protein
Antibody generated against a purified Trachemys scripta
vitellogenin protein
Antibody generated against a Ambystoma tigrinum specific
vitellogenin peptide
Antibody generated against a Ambystoma tigrinum specific
vitellogenin peptide
Antibody generated against a Ambystoma tigrinum specific
vitellogenin peptide
Antibody generated against a Ambystoma tigrinum specific
vitellogenin peptide
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Appendix 2 - Body Weights of Salamanders from
Experiment 1
Vehicle 1
Vehicle 2
Vehicle 3
Vehicle 4
Vehicle 5

188.8
184.2
166.9
183.6
146.1

Average
St Dev
St Error

173.92
17.635
7.887
T Test
0.024

Estrogen 1
Estrogen 2
Estrogen 3
Estrogen 4
Estrogen 5
Estrogen 6
Estrogen 7
Estrogen 8
Estrogen 9
Estrogen 10
Average
St Dev
St Error

153.6
170
153.6
172.7
135.6
150.2
135.5
131.8
151.3
166.3
152.06
14.587
4.613
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Appendix 3 - Total Protein Concentrations of Single Injection
Salamanders from Experiment 1
Averages
E1
E2
E3
E4
E5
E6
E7
E8
E9
E10

25.84
22.5
25.62
43.8
41.37
50.08
24.37
44.34
35.19
30.11
Average
Stand Dev
Stand Error

C1
C2
C3
C4
C5

19.13
17.12
22.1
21.02
17.56
Average
Stand Dev
Stand Error

24.58
35.78
37.41
64.36
55.27
63.06
22.47
55.91
38.22
27.66

25.21
29.14
31.515
54.08
48.32
56.57
23.42
50.125
36.705
28.885

38.397
13.574
3.035

16.14
13.38
38.54
17.76
1.042

0.00025235T test of E/C
17.635
15.25
30.32
19.39
9.301

18.379
9.196
2.908
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Appendix 4 - Total Protein of Salamanders from Experiment 2 Single-Injection

E1M
E2M

Trial 1 Trial 2 Trial 3 Averages T-test
23.53 33.84 23.07
26.813
25.26 30.91 27.64
27.937

E1F
E2F

34.56
32.09

32.2
49.52

21.35
34.79

V1M
V2M

28.99
30.89

12.82
31.86

26.34
24.45

V1F
V2F

23.53
40.94

12.3
50.12

26.17
50.2

Standard Dev
4.293EM
2.837VM
7.045EF
9.041VF

Stand Error
1.753
1.158
2.876
3.691

29.370
38.8000.978
(Females)
22.717
29.0670.667
(Males)
20.667
47.087
0.841
Control
All Estrogen/Control
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Appendix 5 - Total Protein Concentration of Salamanders from Experiment 2 - Multiple
Injection
L1
L2

31.29
33.76

29.96
31.34

42.97
40.29

34.740St Dev
35.130
5.396L1-2

M1
M2
M3

21.24
24.22
15.78

25.83
22.21
12.99

28.84
28.32
16.01

25.303
24.917
14.927

C1
C2
C3

38.47
12.91
29.16

37.37
26.34
34.96

31.51
28.93
33.84

35.783
22.727
32.653

0.0154t-test
very significantly different (m1-3 & C1-3)
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St Error
2.203

5.722M1-3

1.907

7.695C1-3

2.565

Appendix 6 - Body Weights of Salamanders from Experiment 3
Vehicle 1
Vehicle 2
Vehicle 3

7.43
7.43
7.43

Average
St Dev
St Error

7.43
0
0
T Test
0.1943

Estrogen 1
Estrogen 2
Estrogen 3
Estrogen 4
Estrogen 5
Estrogen 6
Estrogen 7
Estrogen 8
Estrogen 9
Estrogen 10
Estrogen 11
Estrogen 12
Average
St Dev
St Error

6.14
5.13
6.94
7.44
7.65
7.46
6.63
7.83
6.3
7.03
6.89
5.6
6.753
0.833
0.240
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Appendix 7 - Body Weights of all Salamanders from Experiment 4
Initial Vehicle 1
Initial Vehicle 2
Initial Vehicle 3
Initial Vehicle 4
Initial Vehicle 5

10.6
11.5
15.1
12
8.9

Atrazine High 1
Atrazine High 2
Atrazine Low 1
Atrazine Low 2
Atrazine Low 3

12.2Avg
12.4St Dev
12.9St Error
9.2
12.8

Vehicle 6

13.2

Atrazine Low 4

18.5Avg

Vehicle 7

13.2

Atrazine Low 5
Atrazine Low 6

12.3St Dev
10.7St Error

Avg
St Dev
St Error

Estrogen 1
Estrogen 2
Estrogen 3
Estrogen 4
Estrogen 5
Estrogen 6
Estrogen 7
Estrogen 8
Estrogen 9

12.07 Initial
All
1 Avg
Vehicles
2.011
11.62
12.071
0.760
Avg
T Test
St Dev
0.237
0.141 St Error
E/C
InitC/E
13.3
13.8
12.3
Aroclor 1221 High 1
14.1
Aroclor 1221 High 2
13.1
Aroclor 1221 High 3
10.7
Aroclor 1221 High 4
11.9
Aroclor 1221 High 5
13.9
14.6

Avg

13.07
8

St Dev
St Error

1.238
0.413

Aroclor 1221 High 6
Aroclor 1221 Low 1
Aroclor 1221 Low 2

Aroclor 1221 Low 3

Aroclor 1221 Low 4
Aroclor 1221 Low 5
Aroclor 1221 Low 6

12.625
2.683
0.949

14.5
11.1
9.2Avg
11St Dev
8St Error

12.3High
0.141
0.1

12.733Low

3.165
1.292

12.1St Dev
9.3St Error
13

Atrazine
High/Init
0.706 Controls
Atrazine
Low/Init
0.529 Controls

0.663(all a/e)

11.1High
2.353
0.961

12.8
15.5
15.8

16Avg

T Test
Atr H/L
0.860

13.617Low

2.657
1.085

T Test
Aroclor
H/L
0.113
Aroclor
High/Init
0.720 Controls
Aroclor
Low/Init
0.219 Controls

0.812(AllA/V)
Avg
12.358St Dev
St Error
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2.73
0.78

Appendix 8: An example of the Densitometry Plots
(This is of Figure 8)

Control Albumin Peak
Fraction 28

Estrogen-Treated Albumin Peak
Fraction 28
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Control Albumin Peak
Fraction 29

Estrogen-Treated Albumin Peak
Fraction 29
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Control Albumin Peak
Fraction 30

Estrogen-Treated Albumin Peak
Fraction 30 – Still no Vitellogenin present
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Control Vitellogenin Peak
Fraction 34 – Albumin no longer present

Estrogen-Treated Vitellogenin Peak
Fraction 34 – Albumin no longer present

120

Control Vitellogenin Peak
Fraction 35 – Albumin no longer present

Estrogen-Treated Vitellogenin Peak
Fraction 35 – Albumin no longer present
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